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ABSTRACT 
TRPM2 is a non-selective cation channel which is permeable to calcium. Although 
expression is highest in the brain, the physiological role for TRPM2 in neurons is 
unknown. Furthermore, our understanding of the pathways regulating TRPM2 channel 
function requires further investigation. In this thesis, we identified that TRPM2 is 
required for NMDAR-dependent LTD. No change in NMDAR expression or function 
was observed following genetic deletion of TRPM2. Instead, the loss of NMDAR-LTD 
in TRPM2 knockout mice results from diminished GSK-3β activation. We next 
examined whether age in vitro could facilitate TRPM2 currents. We demonstrate that 
diminished glutathione with age results in the loss of basal TRPM2 channel inhibition. 
We subsequently demonstrate that TRPM2 currents are enhanced by oligomeric Aβ, a 
peptide proposed to initiate the majority of toxic effects observed in Alzheimer’s 
disease. Potentiation of TRPM2 may involve Fyn, a tyrosine kinase implicated in 
oxidative stress and neurotoxicity. We demonstrate that Fyn is capable of interacting 
with and phosphorylating TRPM2. Acute application of Fyn through the patch pipette 
potentiates TRPM2 currents, and a Fyn(39-57) mimetic peptide significantly attenuates 
currents in cultured hippocampal neurons. These results are the first to establish a role 
for TRPM2 in neurons, and also implicate TRPM2 in neurodegenerative disorders such 
as Alzheimer’s disease. 
KEYWORDS: 
TRPM2, calcium, synaptic plasticity, LTD, NMDA, GSK-3β, aging, glutathione, Fyn, 
Alzheimer’s disease 
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1.1 INTRODUCTION 
Transient receptor potential melastatin type 2 (TRPM2) is a non-selective cation 
channel permeable to calcium (Ca2+), which belongs to the TRP family of ion channels. 
TRPM2 mRNA is the most abundant of TRP channels in the Central Nervous System 
(CNS) (Fonfria, Murdock et al., 2006). Several studies have demonstrated a clear role 
for TRPM2 in cell death in response to oxidative stress in a variety of cell types, 
including neurons (Takahashi et al., 2011); however, a physiological role for TRPM2 in 
the CNS has not yet been elucidated. TRPM2 was first cloned and characterized in 2001 
(Perraud et al., 2001). Although several factors which activate, inhibit, and modulate 
TRPM2 have been identified over the past decade, research into the regulation of 
TRPM2 and potential implications for normal function and pathology is still in its 
infancy. The purpose of this PhD thesis is to investigate the role of TRPM2, and how 
this channel is regulated in hippocampal pyramidal neurons. 
 
1.2 TRANSIENT RECEPTOR POTENTIAL MELASTATIN 2 (TRPM2) 
The Transient receptor potential (TRP) family of ion channels are non-selective 
cation channels. The first TRP gene was originally identified in Drosophila, where TRP 
participates in phototransduction (Montell & Rubin, 1989). To date, 28 TRP channels 
have been discovered in mammals, which are divided into six subfamilies including the 
canonical (C), vanilloid (V), polycystin (P), mucolipin (ML), ankyrin (A), and 
melastatin (M) subfamilies (Clapham, 2007; Nilius & Owsianik, 2011). 
 The first member of the TRPM subfamily to be described, TRPM1, was 
originally identified in melanomas, where its expression is negatively correlated with 
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tumour cell proliferation and metastasis (Duncan et al., 1998). Since this time, eight 
different TRPM family members (TRPM1-TRPM8) have been described in mammals 
(Clapham, 2007). TRPM2, previously known as TRPC7 and LTRPC2, is located on 
chromosome 21q22.3 in humans (Nagamine et al., 1998). The gene contains 33 exons 
over 90kb, and produces a 5876bp full-length transcript which codes for a 1503 amino 
acid protein. In addition to the full length form of the protein, several splice variants of 
TRPM2 have also been identified. These include: TRPM2-∆N, a variant with deletion 
of amino acids 538-557; TRPM2-∆C, a variant with a deletion of amino acids 1292-
1325; TRPM2-∆N∆C, missing both regions 538-557 and 1292-1325; striatum short 
form TRPM2 (SSF-TRPM2), a variant identified in the striatum in which the first N-
terminal 214 amino acids are deleted; TRPM2-S, a variant in which a stop codon is 
introduced at amino acid 995, producing a non-functional protein which is truncated 
after the second transmembrane domain (Uemura et al., 2005; Wehage et al., 2002; 
Zhang et al., 2003). TRPM2 mRNA assessed by quantitative real-time polymerase 
chain reaction (qRT-PCR) demonstrates a near ubiquitous expression in all tissues 
examined, with the exception of bone and cartilage. TRPM2 mRNA is most abundant in 
the brain (Fonfria, Murdock et al., 2006).  
The structure of TRPM2 is proposed to include 6 transmembrane domains, with 
a pore-forming re-entry loop between transmembrane domains 5 and 6. The amino and 
carboxy terminal regions of the protein are cytoplasmic, and contain regulatory features 
for the channel (Figure 1.1). The amino-terminus of TRPM2 contains a TRPM 
homology domain, a region of approximately 700 amino acids (aa) which is largely 
conserved across all TRPM family members (Kraft & Harteneck, 2005). Additionally, 
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an IQ-like motif identified to be involved in Ca2+-Calmodulin binding to the channel 
participates in TRPM2 activation (Tong et al., 2006). In the C-terminal portion of 
TRPM2, the coiled-coiled motif is predicted to participate in interactions between 
TRPM2 proteins and formation of the functional tetrameric form of the channel (Jiang, 
2007).  Importantly, the C-terminus of TRPM2 also includes a nucleoside diphosphate-
linked moiety X-type homology motif (NUDT9-H) which is required for gating of the 
channel by adenosine diphosphate ribose (ADPR), an intracellular ligand for TRPM2. 
The NUDT9-H region shares 39% sequence homology to NUDT9, a mitochondrial 
ADPR hydrolase that converts ADPR to adenosine monophosphate (AMP) and ribose-
5-phosphate, but demonstrates less than 1% of the enzymatic activity (Perraud et al., 
2001; Shen et al., 2003). The reduction in activity has been attributed to amino acid 
substitutions in the NUDT9-H motif at E1405I/F1406L. Indeed, when these residues are 
replaced in TRPM2, gating of TRPM2 by ADPR is lost (Kuhn & Luckhoff, 2004). 
The TRPM2 channel has a single channel conductance of approximately 60-
80pS and a linear current-voltage relationship, with a reversal potential of 0mV (Heiner 
et al., 2003; Perraud et al., 2001; Sano et al., 2001). These characteristics demonstrate 
that the channel is not gated by voltage, and is a non-selective cation channel. The 
permeability ratio of Ca2+ to Na+ (PCa:PNa) is approximately 0.7, demonstrating that the 
inward current is predominantly carried by Na+ (Kraft et al., 2004; Sano et al., 2001); 
however, the long open time of several hundred milliseconds allows for substantial Ca2+ 
influx into the cell (Kraft et al., 2004; Perraud et al., 2001; Sano et al., 2001). 
 
 
  
 
 
 
FIGURE 1.1 TRPM2 Structure.
TRPM2 is a 1503aa protein, comprised of intracellular amino and carboxy
regions, and six transmembrane segments with a re
segments 5 and 6. The amino
(CaM) which participates in channel activation. The carboxy terminus contains a highly
conserved TRP box (TRP), a coiled
tetrameric assembly, and the nucleoside diphosphate
motif (NUDT9-H) which binds adenosine diphosphate ribose (ADPR), the intracellular 
agonist for TRPM2. 
 
 
-entry pore forming loop between 
-terminus contains a Ca2+-Calmodulin binding motif 
-coiled region (CCR) which may participate in 
-linked moiety X
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 terminal 
 
-type homology 
6 
 
 
TRPM2 represents a particularly unique channel in that it is activated in 
response to reactive oxygen and nitrogen species (ROS/RNS) (Takahashi et al., 2011). 
In a variety of cell types, several groups have demonstrated that TRPM2 activation by 
ROS/RNS can elicit a toxic influx of Ca2+ which leads to cell death (Takahashi et al., 
2011). The mechanism for channel activation following exposure to ROS/RNS has been 
attributed predominantly to generation of ADPR, a ligand of TRPM2 which was 
accurately predicted based on homology of the NUDT9-H domain of TRPM2 to 
NUDT9 (Perraud et al., 2001). Oxidative stress may generate ADPR through two 
cellular mechanisms. First, ROS/RNS exposure may lead to DNA damage and 
activation of polyADPR polymerase (PARP) and polyADPR glycohydrolase (PARG). 
These enzymes convert nicotinamide adenine dinucleotide (NAD+) into polyADPR, and 
break down polyADPR into monomeric ADPR, which is then capable of activating 
TRPM2 channels (Blenn et al., 2011; Fonfria et al., 2004). The second proposed 
mechanism of ROS/RNS activation of TRPM2 involves the breakdown of NAD+ into 
ADPR by NUDT9 ADPRase activity in the mitochondria. Indeed, when a 
mitochondrial targeted form of NUDT9 was expressed in human embryonic kidney-293 
(HEK-293) cells stably expressing an inducible flag-tagged human TRPM2 (HEK293-
TRPM2), activation of TRPM2 in response to H2O2 treatment was significantly 
suppressed (Perraud et al., 2005). The half maximal concentration for activation of 
TRPM2 by ADPR (EC50) is estimated at 70 - 90µM (Perraud et al., 2001; Sano et al., 
2001). Importantly, intracellular concentrations of ADPR fall within the range for 
endogenous TRPM2 activation at 5-80µM (Gasser & Guse, 2005; Heiner et al., 2006). 
A variant of TRPM2 (TRPM2-∆C) which is insensitive to ADPR still responds to H2O2 
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exposure, raising the possibility that activation of TRPM2 by oxidative stress may also 
occur independent of ADPR production (Wehage et al., 2002). 
In addition to ADPR, several studies have proposed that NAD+ is capable of 
directly activating TRPM2 channels (Hara et al., 2002; Inamura et al., 2003; Sano et al., 
2001); however, this finding has not been consistently reproduced in the literature 
(Perraud et al., 2001; Wehage et al., 2002). In comparison to activation of TRPM2 by 
ADPR, the time period between NAD+ application and TRPM2 activation is 
significantly longer, raising the possibility that NAD+ activates TRPM2 indirectly 
following the generation of ADPR (Sano et al., 2001). Similarly, whether Ca2+ is 
capable of directly activating TRPM2 channels or whether its actions on TRPM2 simply 
enhance response to ADPR is under debate. It is well accepted that intracellular Ca2+ 
facilitates TRPM2 currents generated by ADPR (Heiner et al., 2006; McHugh et al., 
2003; Olah et al., 2009; Perraud et al., 2001; J. Starkus et al., 2007). The co-operativity 
between ADPR and Ca2+ has been attributed to the binding of 4 Ca2+ ions near the pore 
entrance of TRPM2, and also through an interaction between a Ca2+/Calmodulin 
complex with the IQ-like motif on the N-terminus of TRPM2 (Csanady & Torocsik, 
2009; Tong et al., 2006). In support of direct activation of TRPM2 by Ca2+, TRPM2 
splice variants which do not respond to ADPR (TRPM2-∆N, TRPM2-∆C, TRPM2-
∆N∆C, and SSF-TRPM2) are still activated by 10µM Ca2+ (Du, Xie, & Yue, 2009a). 
Importantly, intracellular Ca2+
 
in micro- and nano-domains are estimated to range as 
high as 1-100µM (Fakler & Adelman, 2008). Whether Ca2+ reaches this concentration 
near TRPM2 and could represent a physiologically relevant gating mechanism remains 
to be determined. 
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In addition to activation of TRPM2 by the above mechanisms, TRPM2 currents 
are augmented by cyclic ADPR (cADPR), nicotinic acid adenine dinucleotide 
phosphate (NAADP), arachidonic acid, and temperature. TRPM2 current potentiation 
by cADPR and NAADP has been demonstrated by several groups; however, whether 
they act as direct agonists, contribute to channel activation by conversion to ADPR, or 
co-activate the channel, shifting the concentration response curve of ADPR required for 
channel activation, is still unclear (Beck et al., 2006; Kolisek et al., 2005; Lange et al., 
2008; Tao et al., 2011; Toth & Csanady, 2010). Arachidonic acid has also been 
demonstrated to facilitate TRPM2 currents, potentially in response to increased release 
of intracellular Ca2+ (Hara et al., 2002). Lastly, heat enhances the permeability of 
TRPM2 currents, augmenting currents elicited with β-NAD+ or ADPR at physiological 
temperatures (Togashi et al., 2006). 
In addition to endogenously occurring agonists of TRPM2, an acidic 
environment has been shown to inhibit the channel. An extracellular acidic environment 
reversibly suppresses TRPM2 currents at a half-maximal inhibitory concentration (IC50) 
ranging from pH 4.7 - 6.5, depending on the concentration of Ca2+ used in solutions. 
These studies suggest that extracellular pH inhibits TRPM2 channels by binding to 
external residues and/or permeation of H+ and subsequent competition for intracellular 
Ca2+ binding sites on the channel, resulting in reduced channel conductance (Du, Xie, & 
Yue, 2009b; J. G. Starkus, Fleig, & Penner, 2010; W. Yang et al., 2010). Similarly, an 
intracellular acidic environment also inhibits TRPM2 currents with an IC50 of pH 6.7 by 
inducing channel closure, through an interaction with Asp933 located on the intracellular 
side of the channel between transmembrane domains 4 and 5 and/or competing for 
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intracellular Ca2+ binding sites (Du, Xie, & Yue, 2009b; J. G. Starkus et al., 2010; W. 
Yang et al., 2010). 
Preliminary evidence also implicates glutathione (GSH), a naturally occurring 
antioxidant, as an endogenous inhibitor of TRPM2 channels. Extracellular GSH inhibits 
cell death induced by H2O2 and TNF-α in insulinoma and monocyte cell lines (Hara et 
al., 2002). Furthermore, chemical depletion of intracellular GSH induces an increase in 
intracellular Ca2+ through TRPM2 channels in glia and dorsal root ganglion sensory 
neurons (Lee et al., 2010; Naziroglu et al., 2011). These studies propose that depletion 
of GSH activates TRPM2 through a subsequent increase in oxidative stress, but do not 
establish a mechanism of inhibition nor do they determine whether or not endogenously 
occurring changes in GSH modulate TRPM2 currents. 
At present, there are no specific antagonists to TRPM2. The channel is inhibited, 
albeit non-selectively, by various pharmacological agents, including N-(p-
amycinnamoyl) anthranilic acid (N-ACA), econazole, clotrimazole, and flufenamic acid 
(Eisfeld & Luckhoff, 2007; Olah et al., 2009). Research elucidating physiological roles 
of TRPM2 has been hindered by the lack of a specific antagonist. In order to 
specifically assess the role of TRPM2 in various processes, TRPM2 knockout mice 
have been generated (Yamamoto et al., 2008). Studies employing a pharmacological 
and/or genetic approach to inhibiting TRPM2 currents have increased our understanding 
of the pathological and physiological roles of TRPM2. 
Cell death in response to oxidative stress is the best characterized role for 
TRPM2. Initial evidence using heterologous expression of TRPM2 in HEK cells, and 
endogenous expression of TRPM2 in insulinoma and monocyte cell line cells revealed 
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that TRPM2 conferred susceptibility to cell death in response to treatment with H2O2 
(Hara et al., 2002). A role for TRPM2 in cell death has since been confirmed in a 
variety of cell types including neuronal cell populations in response to H2O2, TNFα, and 
Aβ peptide (Fonfria et al., 2005; Jia et al., 2011; Kaneko et al., 2006; Takahashi et al., 
2011; Xie, Macdonald, & Jackson, 2010).
 
In addition to the established role of TRPM2 in oxidative stress-mediated cell 
death, physiological roles for TRPM2 are being actively investigated. For example, 
TRPM2 has been implicated in insulin secretion from pancreatic β-cells (Inamura et al., 
2003; Togashi et al., 2006; Uchida et al., 2011). A role for TRPM2 in cytokine 
production in monocytes/macrophages has also been established. In particular, 
activation of TRPM2 leads to the production of cytokines including CXCL8 (previously 
known as interleukin-8 [IL-8]), IL-6, IL-10, and TNF-α (Wehrhahn et al., 2010; 
Yamamoto et al., 2008). Increased cytokine production through activation of TRPM2 
promotes inflammation. Interestingly, TRPM2 also appears to dampen the 
inflammatory response through cellular depolarization and subsequent reduction of 
ROS production in phagocytes, thereby minimizing excess inflammation (Di et al., 
2011). Lastly, oxidative stress acts on TRPM2 to enhance endothelial cell permeability 
by opening interendothelial junctions, although the precise mechanism(s) involved 
requires further investigation (Hecquet et al., 2008). Although the highest level of 
TRPM2 expression is found in the brain, a physiological role for TRPM2 in neuronal 
cells has not yet been identified. Investigation into the physiological role of TRPM2 in 
neurons and regulatory pathways in these cells is therefore of critical importance. 
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1.3 TRPM2 IN THE CENTRAL NERVOUS SYSTEM 
TRPM2 mRNA is most abundant in brain tissue (Fonfria, Murdock et al., 2006). 
At present, TRPM2 expression in the CNS has been demonstrated in microglia, 
astrocytes, and in neuronal populations in the hippocampus, substantia nigra, striatum, 
cortex, and dorsal root ganglion (DRG) sensory neurons in the spinal cord (Fonfria et 
al., 2006; Hill et al., 2006; Kaneko et al., 2006; Kraft et al., 2004; Lee et al., 2010; Olah 
et al., 2009). The role of TRPM2 in normal physiological functions and its involvement 
in CNS disease is gaining increasing attention. 
Activation of TRPM2 by oxidative stress and role in cell death implicates 
TRPM2 in various neurological disorders. Genetic studies have associated single 
nucleotide polymorphisms (SNPs) in TRPM2 to an increased susceptibility for bipolar 
disorder (Kostyrko et al., 2006; McQuillin et al., 2006; Xu et al., 2006; Xu et al., 2009). 
A single SNP (P1018L) in TRPM2 has also been identified in tissue from Guamanian 
amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) subjects (Hermosura 
et al., 2008). Whether other neurological disorders are associated with TRPM2 
mutations requires further investigation. 
Stroke is associated with increased oxidative stress and calcium dysregulation, 
which implicates TRPM2 in the neurodegenerative processes following ischemia. In 
cultured cortical neurons, cell death following treatment with H2O2 (50µM for 6 hours, 
or 1mM for 20 minutes) was greatly attenuated by knockdown of TRPM2, providing 
evidence that TRPM2 promotes cell death in neurons in response to oxidative stress 
(Kaneko et al., 2006). In a transient middle cerebral artery occlusion (tMCAO) rat 
model of ischemia, expression of TRPM2 mRNA is elevated from 1-4 weeks following 
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induction of the stroke. This was attributed to transcriptional upregulation of TRPM2 in 
microglia in response to oxidative stress and the cytokine IL-1β (Fonfria et al., 2006). 
Pharmacological inhibitors and RNA interference with shRNA targeting TRPM2 
reduced infarct volume in vivo and decreased neuronal cell death in vitro following 
oxygen glucose deprivation (OGD). Interestingly, this protection appears to be specific 
to males, suggesting a potential gender difference in contributions of TRPM2 to 
ischemic cell death (Jia et al., 2011). 
In addition to a potential role in stroke, TRPM2 has also been implicated in 
Alzheimer’s disease (AD). Primary striatal cultures exposed to 20µM monomeric β-
amyloid, the main component of senile plaques in AD, demonstrate an increase in 
intracellular calcium and cell death which was partially blocked when cultures were 
transfected with a dominant negative splice variant of TRPM2 (Fonfria et al., 2005). Of 
note, these experiments were performed in striatal cultures; however, AD presents with 
degeneration of the basal forebrain cholinergic neurons, entorhinal cortex, 
hippocampus, and cortex (Coyle, Price, & DeLong, 1983; Gomez-Isla et al., 1996) and 
therefore the validity of a striatal culture system to model AD is questionable. 
Furthermore, 20µM of Aβ which had not been oligomerized was used to induce calcium 
influx and cell death; however, it is the oligomeric form of Aβ that has been shown to 
induce an influx of intracellular calcium, significantly increase oxidative stress, and be 
particularly toxic to neurons (De Felice et al., 2007; Demuro et al., 2005; Lambert et al., 
1998). Although this study implicates TRPM2 in Alzheimer’s pathology, further 
research into the role of TRPM2 is required to validate and expand upon this 
preliminary study.  
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Recent evidence also suggests that TRPM2 may play a role in spinal cord injury 
and neuropathic pain. In a rat model of spinal cord injury, intraperitoneal (IP) injection 
of clotrimazole conjugated to polyethylene glycol significantly reduced lipid 
peroxidation, an indicator of oxidative stress, when administered 5 minutes after spinal 
cord compression (Usul et al., 2006). It is unclear whether inhibition or knockdown of 
TRPM2 results in higher functional performance compared to untreated controls in a 
spinal cord injury model. Additionally, a recent study demonstrated that TRPM2 
mRNA is elevated following sciatic nerve injury. When compared with WT littermate 
controls, TRPM2 knockout mice show a reduced immune response and attenuation of 
the heightened mechanical and thermal pain responses elicited by sciatic nerve injury, 
suggesting that TRPM2 plays a role in neuropathic pain (Haraguchi et al., 2012).  
 Combined, the above data provides genetic, in vitro, and in vivo evidence that 
TRPM2 may be a key player in a variety of CNS disorders. Importantly, a role for 
TRPM2 in non-pathological processes in the CNS has not yet been elucidated. To 
determine potential physiological roles of TRPM2, it is important to consider location 
of expression and channel characteristics. For example, the permeability of TRPM2 to 
Ca2+ and activation by oxidative stress are defining characteristics of TRPM2. In the 
CNS, Ca2+ plays important roles in development, signal transduction, protein 
expression, neurotransmitter release, and synaptic plasticity. As mentioned earlier, 
TRPM2 is expressed in neuronal populations in the hippocampus, substantia nigra, 
striatum, cortex, and DRG sensory neurons (Chung, Freestone, & Lipski, 2011; Fonfria 
et al., 2005; Fonfria et al., 2006; Hill et al., 2006; Kaneko et al., 2006; Kraft et al., 2004; 
Lee et al., 2010; Naziroglu et al., 2011; Olah et al., 2009; Uemura et al., 2005). 
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Expression of TRPM2 in the hippocampus is particularly interesting because this region 
of the brain is critically involved in learning and memory, and neurons in this region of 
the brain also demonstrate a selective vulnerability to various pathological insults 
(Mattson, Guthrie, & Kater, 1989; Wang & Michaelis, 2010). Within the hippocampus, 
TRPM2 mRNA is localized to the pyramidal cell layer, and preliminary evidence 
demonstrates a predominantly extrasynaptic distribution in cultured hippocampal 
neurons (Olah et al., 2009). TRPM2 currents in these cells can be activated by 
ROS/RNS exposure, or by calcium influx through voltage-dependent calcium channels 
(VDCC) or NMDARs in the presence of intracellular ADPR (Olah et al., 2009). 
Therefore, a greater understanding of VDCCs, NMDARs, and synaptic plasticity may 
help to establish a potential physiological role for TRPM2 in hippocampal pyramidal 
neurons. 
 
1.4 VOLTAGE-DEPENDENT CALCIUM CHANNELS 
Voltage-dependent calcium channels (VDCCs) allow for the influx of Ca2+ following 
neuronal depolarization. Strong depolarization will activate L-type, N-type, P/Q-type, 
and R-type VDCCs, while a more modest depolarization will activate T-type VDCCs 
(Benarroch, 2010). VDCC all contain an obligate pore-forming α-subunit which 
determines gating properties of the channel. VDCC α subunits include the Cav1, Cav2, 
and Cav3 subunits. The Cav1 α subunit is expressed in L-type VDCCs, the Cav2 α 
subunit is expressed in N-, P/Q-, and R-type channels, and the Cav3 α subunit is 
expressed in T-type channels. The α subunit of most VDCCs are also found in complex 
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with a β-, α2δ, and γ- subunits which modulate trafficking and channel gating (Arikkath 
& Campbell, 2003; Benarroch, 2010).  
 Within hippocampal neurons, VDCCs are involved in both pre- and post-
synaptic functions (Catterall, 2011). L-type VDCC are expressed predominantly on the 
neuronal soma and proximal dendrites where they participate in incorporating synaptic 
input and coupling Ca2+ influx to gene transcription  (Bading, Ginty, & Greenberg, 
1993; Christie et al., 1995; Christie, Schexnayder, & Johnston, 1997; Deisseroth, Heist, 
& Tsien, 1998; Hell et al., 1993; Murphy, Worley, & Baraban, 1991; Weisskopf, Bauer, 
& LeDoux, 1999).  In contrast, N, P/Q-, and R-type channels demonstrate a presynaptic 
distribution and are mainly involved in neurotransmitter release (Catterall & Few, 
2008). Due to the low threshold of depolarization required for activation of T-type 
VDCC and their transient kinetics, T-type VDCC channels are associated with rhythmic 
bursting in neurons (Perez-Reyes et al., 1998). Whether TRPM2 channels uniquely 
couple to specific VDCC has not yet been investigated. 
 
1.5 GLUTAMATE RECEPTORS 
Glutamate is the major excitatory neurotransmitter in the nervous system, and is 
also a key mediator of neurotoxicity. Glutamate receptors are classified as either 
metabotropic or ionotropic. The metabotropic glutamate receptors (mGluR1-8) couple 
to G-proteins to activate downstream signaling cascades. The ionotropic glutamate 
receptors are ligand-gated non-selective cation-permeable ion channels, allowing for the 
movement of Na+, K+, and sometimes Ca2+. These receptors include the N-methyl-ᴅ-
aspartate (NMDA), α-amino-3-hyroxy-5-methyl-4-isoazoleproprionic acid (AMPA), 
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and 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (kainate) receptors (Kew & 
Kemp, 2005). 
 AMPA Receptors (AMPARs) in the CNS are tetramers. Subunits are termed 
GluR1-4.  In the hippocampus, AMPARs are contain GluR2 in combination with GluR1 
or GluR3 subunits, with GluR2-GluR1 being the most common at CA3-CA1 synapses 
(W. Lu et al., 2009). In the adult CNS, presence of the GluR2 subunit abolishes Ca2+ 
permeability of AMPA Receptors; therefore, the majority of AMPAR current is 
attributed to influx of Na+ and efflux of K+ ions (Geiger et al., 1995; Hollmann, Hartley, 
& Heinemann, 1991). Synaptic transmission in the hippocampus is predominantly 
mediated through these receptors (Derkach et al., 2007). 
NMDARs are comprised of two obligate GluN1 subunits in combination with 
two GluN2 subunits (GluN2 A-D) or two GluN3 subunits (GluN3 A or B) (Kew & 
Kemp, 2005). Under normal physiological conditions, the release of glutamate during 
synaptic transmission results in the activation of AMPARs, depolarizing the post-
synaptic cell. This change in voltage relieves the Mg2+ block of NMDA channels, 
permitting cation influx following co-activation by glutamate and glycine. This results 
in an acute, non-toxic rise in intracellular Ca2+ that is buffered by a variety of 
mechanisms (Derkach et al., 2007; Mattson, 2007). In pathological conditions, 
excessive Ca2+ entry via NMDARs has been shown to be particularly neurotoxic 
(MacDonald, Xiong, & Jackson, 2006; Sattler et al., 1998; Tymianski et al., 1993). 
In the adult hippocampus, GluN2A and GluN2B containing NMDARs are the 
most abundant. GluN2B-containing NMDAR demonstrate a largely extrasynaptic 
distribution, while synaptic NMDARs are comprised predominantly of GluN2A-
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containing NMDARs (Monyer et al., 1994). Interestingly, NMDARs have been 
associated with dichotomous signaling toward survival and apoptosis pathways, and 
also in synaptic plasticity. Although still a matter of debate, some explanations for the 
differences in signaling include synaptic vs. extrasynaptic localization of NMDARs, 
stimulus intensity, and subunit specific differences between GluN2B and GluN2A 
(Choi, 1985; Dudek & Bear, 1992; Hardingham, Fukunaga, & Bading, 2002; 
Ikonomidou et al., 1999; Ikonomidou, Stefovska, & Turski, 2000; L. Liu et al., 2004; Y. 
Liu et al., 2007; Mulkey & Malenka, 1992; Sattler et al., 2000). 
 
1.6 SYNAPTIC PLASTICITY 
Synaptic plasticity describes the strengthening or weakening of connections 
between neurons. These experience-dependent changes are implicated in learning and 
memory (Ho, Lee, & Martin, 2011; Malenka & Bear, 2004; Whitlock et al., 2006). A 
strong stimulus results in the strengthening of synaptic connections (potentiation), 
whereas a weak stimulus will produce a weakening of the synaptic connection 
(depression). When these changes are maintained for minutes to hours, the changes are 
termed long-term potentiation (LTP) or long-term depression (LTD). Long-term 
changes in synaptic strength require the synthesis of new proteins (Greer & Greenberg, 
2008; Kandel, 2001). Furthermore, pre-synaptic, trans-synaptic, and post-synaptic 
modifications are also involved in the induction and maintenance of experience-
dependent synaptic changes (Ho et al., 2011; Malenka & Bear, 2004). Pre-synaptic 
mechanisms of synaptic plasticity often alter the likelihood of neurotransmitter release 
(Catterall & Few, 2008). At the synaptic cleft, release of trans-synaptic signaling 
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molecules can activate a variety of signaling cascades in the pre-synaptic neuron 
(Regehr, Carey, & Best, 2009). Furthermore, LTP and LTD both involve alterations to 
adhesion molecules which alter signaling cascades and promote remodeling of the 
synapse (Dalva, McClelland, & Kayser, 2007). Post-synaptic changes underlying LTP 
and LTD include post-translational modifications and altered protein trafficking (Ho et 
al., 2011; Santos et al., 2009).  
LTP and LTD require influx of Ca2+ (Cavazzini, Bliss, & Emptage, 2005; Greer 
& Greenberg, 2008; Lisman, Schulman, & Cline, 2002; MacDonald, Jackson, & 
Beazely, 2006). Importantly, calcium-permeable TRPM2 channels are expressed and 
functional in hippocampal pyramidal neurons (Olah et al., 2009); therefore, a greater 
understanding of synaptic plasticity at these synapses is required to explore a potential 
physiological role for TRPM2.  
NMDAR-dependent LTP and LTD is the major form of synaptic plasticity at 
hippocampal CA3-CA1 glutamatergic synapses (MacDonald et al., 2006). In the 
hippocampus, LTP and LTD are experimentally induced by stimulation of the Schaffer 
collateral pathway. This activates axon collaterals of glutamatergic neurons in the CA3 
area of the hippocampus which synapse upon CA1 pyramidal neurons. The resulting 
excitatory post-synaptic potential (EPSP) can then be recorded by field recordings 
extracellular of the CA1 neurons (Figure 1.2).  Basal stimulation (~0.1Hz) results in an 
EPSP mediated predominantly by AMPAR. When a low-frequency (1Hz) or high-
frequency (100Hz) stimulation is applied, NMDAR are also activated, allowing for 
influx of Ca2+ and induction of LTD or LTP, respectively (Collingridge, Kehl, & 
McLennan, 1983; Collingridge, Herron, & Lester, 1988; MacDonald et al., 2006). 
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Activation of NMDAR is required for synaptic plasticity in vitro and in vivo 
(Collingridge et al., 1983; Davis, Butcher, & Morris, 1992; Morris et al., 1986).  
The bidirectional plasticity induced by activation of NMDARs suggests that the 
amount of glutamate released, distribution or subtype of activated NMDARs, and/or the 
amount, kinetics, or subcellular location of Ca2+ influx may activate different 
downstream pathways and uniquely alter the post-synaptic response to stimulation 
(MacDonald et al., 2006). The large increase in intracellular Ca2+ following a high 
frequency stimulation activates calcium/calmodulin-dependent protein kinase II 
(CaMKII), which phosphorylates AMPARs, increasing conductance of the receptor 
(Lisman et al., 2002; Malenka & Bear, 2004). Several other kinases including protein 
kinase C (PKC), mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-
kinase (PI3K) also participate in phosphorylation of AMPAR, trafficking of AMPAR to 
the synapse, and structural modifications to synapses which increase basal synaptic 
transmission (W. Lu et al., 2001; Malenka & Bear, 2004). Furthermore, the tyrosine 
kinase Fyn is required for induction of LTP, and the tyrosine kinase Src is activated 
during LTP and participates in enhancing NMDAR function (Grant et al., 1992; Salter 
& Kalia, 2004; K. Yang et al., 2011). 
The mechanisms underlying NMDAR-dependent LTD are less well established 
(Collingridge et al., 2010). Briefly, a modest increase in Ca2+ during NMDAR-
dependent LTD promotes the Ca2+ dependent activation of calcineurin, also known as 
protein phosphatase 2B (PP2B). This leads to activation of protein phosphatase 1 (PP1), 
which dephosphorylates AMPAR and decreases receptor conductance. PP1 also de-
phosphorylates and activates glycogen synthase kinase-3β (GSK-3β), which in turn 
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plays a role in the endocytosis of the scaffolding protein post-synaptic density-95 (PSD-
95). Additionally, Ca2+ activates hippocalcin which targets adaptor protein 2 (AP2) to 
the synapse, further increasing AMPAR endocytosis (Collingridge et al., 2010).  Fyn 
also participates in enhancing LTD through phosphorylation and subsequent 
potentiation of GluN2B-containing NMDARs (L. Liu et al., 2004; Nakazawa et al., 
2001; K. Yang et al., 2011).  
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Figure 1.2. Hippocampal slice preparation.  
Shown above is a transverse section of the hippocampus, used to assess synaptic 
plasticity at hippocampal CA3-CA1 synapses. Neurons from the CA3 region of the 
hippocampus project axon collaterals to CA1 pyramidal cells; this is known as the 
Schaffer collateral pathway. Stimulation of the Schaffer collateral pathway depolarizes 
CA3 axons, resulting in glutamate release which acts upon the post-synaptic CA1 
neurons. A recording electrode placed extracellular to the CA1 neurons is used to 
quantify the resulting field excitatory post-synaptic potential (fEPSP). An increase or 
decrease in the fEPSP which is maintained for one hour following various stimulation 
protocols is termed long-term potentiation (LTP) or long-term depression (LTD), 
respectively. Adapted from Ho et al (2011). 
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1.7 AGING AND CALCIUM DYNAMICS 
Homeostatic control of intracellular Ca2+ is important to maintain normal 
physiological function of neurons, including regulation of synaptic plasticity. Prolonged 
or excessive alterations in Ca2+ concentrations can lead to cytotoxicity (Choi, 1985; 
Dirnagl, Iadecola, & Moskowitz, 1999; Orrenius, Zhivotovsky, & Nicotera, 2003).  A 
sudden and excessive increase in intracellular calcium triggers necrotic death in 
neurons, while milder but sustained elevations in calcium promotes delayed cell death 
through a combination of apoptotic and necrotic pathways. We previously reviewed the 
variety of pathways through which Ca2+ levels are altered following ischemia (Belrose 
et al., 2012). In addition to a dysregulation of Ca2+ in pathology, control of Ca2+ levels 
can also be compromised during normal aging in response to energy impairment and 
increased oxidative stress (Figure 1.3) (Mattson, 2007). 
The primary theory underlying the increase in oxidative stress with age was 
described in 1972 and termed the “mitochondrial free radical theory of aging” (Harman, 
1972). Mitochondria are the site of ATP production in the cell, and use the majority of 
the cell’s oxygen for the oxidative phosphorylation process. ROS are a byproduct of this 
process. Oxidative stress in the aging brain leads to lipid peroxidation, DNA damage, 
modifications to ligand and voltage gated Ca2+ channels, and endoplasmic reticulum 
(ER) dysfunction promoting aberrant release of Ca2+ from internal stores (Mattson, 
1998; Mattson, 2007). Furthermore, oxidative stress contributes to mitochondrial 
dysfunction, resulting in diminished ATP levels, and impairing ion-motive ATPases 
which participate in regulating intracellular Ca2+ levels (Mattson, 2007; Mattson, 2007; 
Navarro & Boveris, 2007). This creates a positive feedback loop whereby ROS 
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produced by the mitochondria contribute to cellular dysfunction and reduce efficiency 
of the mitochondria, ultimately resulting in enhanced ROS production. The energy 
impairment and oxidative stress converge on multiple pathways to promote 
dysregulation of neuronal Ca2+ levels during normal aging. 
The consequence of elevated intracellular Ca2+ includes changes in synaptic 
plasticity and cell viability. Interestingly, although NMDAR-dependent LTP is impaired 
with age, the total magnitude of LTP is largely preserved during normal aging, 
potentially through a compensatory upregulation in VDCC-dependent LTP (Robillard et 
al., 2011). LTD, in contrast, is enhanced with normal aging (Norris, Korol, & Foster, 
1996). Combined, these changes in synaptic plasticity produce an age-dependent 
decrease in synaptic strength which may underlie memory impairment with normal 
aging. Furthermore, normal aging also results in a reduction in brain volume in several 
regions of the brain, including the hippocampus (Long et al., 2012; Scahill et al., 2003; 
Sowell et al., 2003). An increase in intracellular Ca2+ levels may underlie the age-
dependent changes in neuronal structure, function, and viability that contribute to the 
observed reduction in brain volume, and altered synaptic plasticity (Foster, 2007; Gant 
et al., 2006; Mattson, 2007; Ouanounou et al., 1999; Villalba et al., 1995). The 
pathway(s) leading to increased intracellular Ca2+ with age is therefore of critical 
importance to our understanding of the age-dependent decrease in synaptic strength and 
increase in susceptibility to neurodegeneration. 
  
  
 
 
 
 
 
 
Figure 1.3. Aging and Calcium Dynamics.
In the brain, normal aging results in a decrease in ATP production resulting in energy 
impairment, and an increase in oxidative stress. These converge to increase intracellular 
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1.8 GLUTATHIONE 
Endogenous mechanisms to protect against ROS mediated damage include the 
endogenously occurring antioxidants superoxide dismutase (SOD), superoxide 
reductase, catalase, and glutathione. These antioxidants may participate in the age-
dependent increase in Ca2+ influx through their modulation of the oxidative stress status 
of the cell. Interestingly, the concentration of glutathione (GSH) decreases with age in 
vitro and in vivo, and therefore represents an interesting potential player in the Ca2+ 
dysregulation observed with age (Chen, Richie, & Lang, 1989; R. M. Liu, 2002; 
Parihar, Kunz, & Brewer, 2008; Rebrin, Forster, & Sohal, 2007; Sasaki et al., 2001). 
GSH is a tripeptide of glutamate, cysteine, and glycine. It is synthesized by the 
enzymes γ-glutamylcysteine followed by glutathione synthases. Both of these steps 
require ATP. The rate limiting step in GSH synthesis is carried out by γ-
glutamylcysteine, due to the limited availability of the cysteine substrate. The 
intracellular concentration of GSH typically ranges from 0.2 - 10mM (Anderson, 1998). 
In the brain, evidence from cultured cells suggests that GSH levels are higher in glial 
cells than in neurons (Dringen & Hamprecht, 1998; Hirrlinger et al., 2002; Raps et al., 
1989). It is less clear whether this is also true in vivo (Miller et al., 2009). 
In the CNS, the primary role of GSH is to decrease oxidative damage by 
reacting with the ROS/RNS superoxide, nitric oxide, hydroxyl radical, and peroxynitrite 
(Clancy et al., 1994; Koppal et al., 1999; Nauser, Koppenol, & Gebicki, 2005; 
Winterbourn & Metodiewa, 1994). The cysteine residue in GSH is also important in 
minimizing protein oxidation. GSH is capable of forming protein adducts through a 
process known as S-glutathionylation to prevent irreversible disulphide bonds between 
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oxidized proteins (Dalle-Donne et al., 2007). The depletion of GSH with age not only 
increases the oxidative stress status of the cell, but may also be associated with 
increased intracellular calcium and subsequent toxicity (Aoyama et al., 2006; Bains & 
Shaw, 1997; Gabby et al., 1996; Jurma, Hom, & Andersen, 1997; Thanislass, 
Raveendran, & Devaraj, 1995). 
 
1.9 FYN KINASE 
A version of this section has been published: 
Yang, K.*, Belrose, J.*, Trepanier, C.H., Lei, G., Jackson, M.F., & MacDonald, J.F. 
(2011). Fyn, a potential target for Alzheimer’s disease. REVIEW. Journal of 
Alzheimer’s Disease, 27(2): 243-252. *these authors contributed equally to this work 
 
The Fyn gene is located at chromosome 6q21. Isoform 1 is a 59kDa protein that 
has the most ubiquitous expression pattern among the three identified Fyn isoforms and 
is highly expressed in the brain (Cooke & Perlmutter, 1989; Goldsmith, Hall, & 
Atkinson, 2002). Homology modeling revealed that the structure is similar to that of 
other Src family kinases (SFKs) such as Src. The structure includes the regulatory 
domain at the C terminus, the catalytic domain (SH1) domain, the linker region, the Src 
homology 2 (SH2) domain, the Src homology 3 (SH3) domain, the unique domain, and 
the Src homology 4 (SH4) domain at the N terminus (Ingley, 2008; Roskoski, 2005; 
Salter & Kalia, 2004; Thomas & Brugge, 1997; Vatish et al., 2009).  
The role of each structural domain has been investigated in Fyn and other SFK 
family members. The SH4 domain of Fyn is a very short motif, containing the signals 
for lipid modification such as myristoylation and palmitoylation that are responsible for 
membrane targeting (Resh, 1993). The importance of this domain was illustrated by 
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observations that the specificity of Fyn in cell signaling depended on its subcellular 
locations (Sicheri & Kuriyan, 1997). This region is followed by the unique N-terminal 
domain, a region of low relative homology to other Src family members (Jelic et al., 
2007). The role of the unique domain remains relatively unexplored; however, it may 
serve as a site for selective interactions with proteins that are specific for each family 
member (Salter & Kalia, 2004). The Fyn SH3 domain is a 60 amino acid sequence that 
interacts with proline rich motifs in a number of signaling molecules and mediates 
various protein-protein interactions. The SH2 domain binds to phosphorylated tyrosine 
residues of interacting proteins (Ingley, 2008; Roskoski, 2005; Salter & Kalia, 2004; 
Thomas & Brugge, 1997; Vatish et al., 2009). The catalytic SH1 domain is highly 
conserved among SFKs. It includes an ATP binding site which is required for the 
phosphoryation of Fyn substrates. The SFK inhibitor PP2 binds to this site, inhibiting 
the phosphorylation of Fyn substrates (Osterhout et al., 1999).  
As with other SFK members, the catalytic function of Fyn is tightly regulated by 
phosphorylation. Foremost, phosphorylation of Y420, located in the activation loop of 
the SH1 domain, is necessary for Fyn activation (Cheng et al., 1991). The degree of Fyn 
activation is often measured by the level of phosphorylated Y420 normalized to total Fyn 
expression. In addition to Y420, phosphorylation of S21 is also involved in the regulation 
of Fyn. Mutation of this site blocked protein kinase A (PKA) phosphorylation of Fyn 
and diminished kinase activity (Yeo et al., 2011). Basal Fyn activity is low due to 
intramolecular interactions between the SH2 domain and phosphorylated Y531 in the C-
terminus and/or between the SH3 domain and the linker region of Fyn. Phosphorylation 
of Fyn at Y531 leads to an inhibition of Fyn activity (Relucio et al., 2009). When this site 
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is dephosphorylated by phosphatases including protein tyrosine phosphatase α (PTPα) 
and Src homology-2-domain-containing phosphatase (SHP1/2), Fyn activity is 
enhanced (Samayawardhena & Pallen, 2010; X. Yang, Dutta, & Shaw, 2010).  
Fyn is an important player in synaptic plasticity. As mentioned previously, Fyn 
is required for induction of LTP at the CA3/CA1 synapse. The requirement for Fyn in 
LTP induction is unique amongst the Src family kinases since knockout of Src -/-, Yes -
/-, and Abl -/- mice show no change in LTP (Grant et al., 1992; Kojima et al., 1997). 
The requirement for Fyn in synaptic plasticity is, at least in part, attributed to regulation 
of NMDA and AMPA Receptors. Potential sites of Fyn phosphorylation on the GluN2B 
subunit of NMDARs include Y1252, Y1336, and Y1472 (Nakazawa et al., 2001). 
Phosphorylation of GluN2B at Y1472 by Fyn enhances GluN2B-NMDAR currents, and 
facilitates LTD (K. Yang et al., 2011). Phosphorylation at these sites may also 
differentially alter NMDAR activity by enhancing degradation of the NMDAR, 
promoting truncation of GluN2 subunits, or by increasing insertion of NMDARs to the 
plasma membrane (Hu et al., 2010; Jurd et al., 2008; Lau & Zukin, 2007; Rong et al., 
2001; Wu et al., 2007). Interestingly, it appears that scaffolding proteins such as post 
synaptic density 93 (PSD-93) or PSD-95 might promote the phosphorylation of 
NMDARs by Fyn (Sato et al., 2008; Tezuka et al., 1999). Furthermore, Fyn 
phosphorylation of GluN2A and GluN2B facilitates the binding of NMDARs to PSD-
95, an interaction that has been linked to toxicity in stroke and in Alzheimer’s disease 
(Aarts et al., 2002; Ittner et al., 2010; Rong et al., 2001).  
Regulation of AMPARs is a crucial mechanism in synaptic plasticity (Santos et 
al., 2009). In neocortical neurons, both BDNF and platelet derived growth factor 
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(PDGF) enhanced surface expression of AMPARs via Fyn. The increase of AMPAR 
was blocked by a PTK inhibitor and was also absent in Fyn -/-mice (Narisawa-Saito et 
al., 1999). Transgenic mice overexpressing either wild type Fyn or constitutively 
activated Fyn have also been generated. Mice overexpressing constitutively active Fyn 
demonstrate enhanced basal synaptic transmission, and facilitated LTP using a weak 
theta-burst stimulation protocol. In contrast, the basal synaptic transmission and the 
threshold for the induction of LTP were not altered in the slices overexpressing wild 
type Fyn (Y. F. Lu et al., 1999). The regulation of NMDARs, AMPARs, and LTP 
induction outlined here demonstrate that Fyn plays a role in synaptic plasticity.  
Importantly, Fyn kinase also plays a role in pathological conditions. For 
example, ROS increases autophosphorylation of Fyn in fibroblasts, and upregulates 
expression of Fyn in a model of chronic myelogenous leukemia (Gao et al., 2009; 
Sanguinetti, Cao, & Corley Mastick, 2003). Whether TRPM2 is also a target of Fyn 
kinase has not yet been explored; however, a recent paper has demonstrated that 
TRPM2 is tyrosine phosphorylated following exposure to oxidative stress. Inhibition of 
Src family kinases with PP2 decreases TRPM2 mediated Ca2+ influx in response to 
H2O2 treatment (Zhang et al., 2007). Combined, this data implicates Fyn in the 
regulation of TRPM2 channels.  
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1.10 HYPOTHESIS AND OBJECTIVES 
TRPM2 is a Ca2+ permeable non-selective ion channel which is activated by 
oxidative stress and participates in cell death in a wide variety of cell types (Takahashi 
et al., 2011). TRPM2 exhibits the highest level of expression in the brain, where it is 
expressed in a variety of cell types including hippocampal pyramidal neurons (Fonfria, 
Murdock et al., 2006; Olah et al., 2009). The physiological role for TRPM2 in these 
cells, and mechanisms which regulate TRPM2 channels, requires investigation. 
Preliminary evidence suggests that TRPM2 may be predominantly localized 
extrasynaptically on these neurons (Olah et al., 2009). Interestingly, some studies report 
that synaptic localization of NMDARs is more closely associated with LTP, while 
extrasynaptically localized NMDARs are more closely associated with LTD (W. Lu et 
al., 2001). Furthermore, substantial evidence supports a role for TRPM2 in cell death 
(Takahashi et al., 2011), and activation of extrasynaptic localization of NMDAR is 
associated with neurotoxicity (Hardingham et al., 2002; Sattler et al., 2000). Therefore, 
we hypothesized that TRPM2 participates in NMDAR-dependent LTD at 
hippocampal CA3-CA1 synapses. 
TRPM2 may also represent a potential mediator of age-dependent Ca2+ 
dysregulation. First, TRPM2 is activated by oxidative stress. Second, it is permeable to 
Ca2+, and TRPM2-mediated calcium-influx leads to cell death in a variety of cell types. 
Third, it is expressed in hippocampal pyramidal neurons which are not only critical for 
learning and memory, but are also particularly susceptible to cell death during ischemia 
and age-dependent neurodegenerative diseases such as Alzheimer’s disease. Therefore, 
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we hypothesized that the expression or activity of TRPM2 is increased with age in 
vitro in cultured hippocampal pyramidal neurons. 
Lastly, TRPM2 is implicated in neuronal cell death in response to oxidative 
stress and Aβ (Fonfria et al., 2005; Kaneko et al., 2006). Whether knockout of TRPM2 
protects against Aβ oligomer-mediated toxicity has not yet been investigated. We 
hypothesized that genetic deletion of TRPM2 will attenuate Aβ oligomer-induced 
reduction in cell viability in cultured hippocampal neurons. Pathways which 
regulate TRPM2 during oxidative stress and/or following exposure to Aβ have not yet 
been elucidated. One potential mediator may be the non-receptor tyrosine kinase, Fyn. 
Oxidative stress induces tyrosine phosphorylation of TRPM2 (Zhang et al., 2007).  Fyn 
kinase SH3 domain participates in protein-protein interactions between Fyn and several 
of its substrates via interactions with proline rich (PxxP) motifs in other proteins.  
Importantly, TRPM2 contains several proline rich motifs (PxxP) in the N- and C- 
terminal portions of TRPM2. We hypothesized that Fyn kinase phosphorylates and 
interacts with TRPM2, and augments TRPM2 currents. 
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2. DEPENDENCE OF NMDA/GSK-3β MEDIATED METAPLASTICITY ON 
TRPM2 CHANNELS AT HIPPOCAMPAL CA3-CA1 SYNAPSES 
 
2.1 Introduction 
The transient receptor potential melastatin 2 channel (TRPM2) is a novel non-
selective cation channel that was initially cloned from the brain, and was subsequently 
identified as an effector of calcium fluxes following oxidative stress (Takahashi et al., 
2011). Functionally, TRPM2 has been linked to cell death, cytokine production, and 
insulin secretion (Takahashi et al., 2011). Interestingly, TRPM2 expression is greatest 
in the central nervous system (CNS) where it may contribute to neurodegenerative 
disease (Takahashi et al., 2011; Xie et al., 2011). We recently demonstrated functional 
expression of TRPM2 in CA1 pyramidal neurons (Olah et al., 2009), in culture and in 
situ. TRPM2 is unique among known ion channels in that it contains a cryptic C-
terminal enzyme domain homologous to the NUDT9 ADP-ribose (ADPR) hydrolase. 
This channel motif serves primarily as the ligand binding domain for ADPR, which is 
required for Ca2+-dependent gating of the channel (Scharenberg, 2005). In hippocampal 
neurons, TRPM2 currents can be activated by voltage-ramps that generate inward Ca2+
 
currents or by strong stimulation of NMDA receptors (NMDARs) (Olah et al., 2009). 
Indeed, high concentrations of ADPR are unable to evoke these currents until activated 
by an influx of Ca2+. The coupling of channel activity to Ca2+ signaling downstream of 
voltage-gated Ca2+ channels and NMDARs suggests that TRPM2 could play a role in 
neuronal signaling or synaptic transmission. Given the lack of selective antagonists, we 
have examined the hypothesis that these channels contribute to synaptic plasticity by 
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employing TRPM2 deficient mice (Yamamoto et al., 2008). 
 
2.1 Methods 
 Experimental animals  
TRPM2 knockout (KO) mice, generated as described previously(Yamamoto et 
al., 2008), were provided by Dr Y Mori. Wild-type (WT) and KO mice used for 
experimentation were derived from heterozygous matings and mouse genotyping was 
performed as previously described (Yamamoto et al., 2008). Mice were kept in a 
pathogen-free environment, and analyses were performed using mice that were matched 
for age. All animal experiments were performed in accordance with protocols approved 
by the University of Western Ontario Animal Use Subcommittee of the University 
Council on Animal Care.  
Whole-cell recording from primary culture  
Mouse hippocampal primary neuronal cultures were prepared from E17-19 
embryos using homozygously bred time pregnant TRPM2 KO mice or WT mice 
according to previously described procedures (MacDonald et al., 1989). Currents were 
recorded at 21-28 days in vitro. Whole-cell voltage-clamp recordings were performed as 
described previously (Olah et al., 2009), with minor adjustments. Briefly, standard 
intracellular solution (ICS) contained (in mM): 150 cesium gluconate, 10 Hepes, and 2 
MgCl2. To record NMDA currents, 11 mM EGTA, 1 mM CaCl2, and 2 mM K2-ATP 
was added to the ICS. TRPM2 currents were recorded with 1 mM ADPR added to the 
ICS. Standard extracellular solution (ECS) contained (in mM): 140 NaCl, 5.4 KCl, 25 
Hepes, 33 glucose, 2 CaCl2, and 0.2 µM TTX. To generate NMDA currents, 50 µM 
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NMDA and 0.5 µM glycine was added to the standard ECS and applied for 3 seconds 
every minute using a multibarrelled rapid perfusion system (SF77B; Warner 
Instruments). For experiments examining the contribution of GluN2B receptor, 1 µM 
Ro 25-6981 (Tocris) was applied after having obtained 3 stable control sweeps in its 
absence. ADPR-primed TRPM2 currents were generated with voltage ramps ( ± 100 
mV over 500ms, applied every 10 sec) in the presence of standard ECS supplemented 
with 1 mM MgCl2 and 1 mM BaCl2. After the TRPM2 current stabilized, or after 10 
minutes of voltage ramps, calcium-free solution was applied (total divalent concentra-
tion maintained by replacing CaCl2 with equimolar BaCl2). Voltage-clamp recordings 
(Vhold = -60 mV) were performed at room temperature (20-22°C) using a Multiclamp 
700A amplifier (Molecular Devices). Data were filtered at 2 kHz, digitized, and 
acquired using pCLAMP and Axoscope software (Molecular Devices).  
Hippocampal slices preparation  
Hippocampal slices were prepared from age-matched TRPM2
-/-
and wild type 
mice (post-natal day 20-30). Briefly, mice were decapitated after isoflurane anesthesia, 
and brains were quickly removed and placed in ice-cold oxygenated (95% O2,5%CO2) 
artificial CSF (ACSF) containing: 124 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 1.3 
mM MgCl2, 2.6 mM CaCl2, 26 mM NaHCO3 and 10 mM glucose (osmolality between 
300 and 310 mOsm). Whole-brain coronal slices (300 µm) containing transverse 
sections of the hippocampus were prepared using a vibrating microtome (VT100E; 
Leica). After a recovery period of 1 h in oxygenated ACSF, hippocampal slices were 
transferred to a recording chamber continuously perfused with oxygenated ACSF (3 ml/ 
min), warmed to 31°C through an in-line solution heater.  
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Field excitatory postsynaptic potentials (fEPSP) recording from Schaffer 
collateral-CA1 synapses. fEPSPs were evoked every 30 s (0.033 Hz) by electrical 
stimulation (100 µs duration) delivered to the Schaffercollateral pathway using a 
concentric bipolar stimulating electrode (25 µm exposed tip) and recorded using glass 
microelectrodes (3-5 MΩ, filled with ACSF) positioned in the stratum radiatum of the 
CA1 area. The stimuli intensity was adjusted to evoke fEPSPs corresponding to 
30~50% of the maximal response evoked in the absence of a contaminating spike 
discharge. The paired-pulse ratio was determined in each slice by delivering pairs of 
stimuli at varying interstimulus intervals (10-1000 ms). For LTD/LTP experiments, 
baseline fEPSPs were monitored for at least 20 min to ensure stability, following 
which synaptic plasticity was induced by repetitive stimulation at the Schaffer 
collaterals delivered at 1, 10, 20, 50 Hz (900 pulses at each frequency) or 100 Hz (four 
1 sec trains delivered 20 sec apart). Following repetitive stimulation, fEPSP slopes 
were monitored for 1 h. Signals were amplified (Axoclamp 700B, Molecular Devices), 
recorded digitally (Digidata 1440A) and analyzed offline using Clampfit 10.  
Whole-cell patch clamp recordings from hippocampal slices  
Visual patch recordings from CA1 pyramidal neurons were performed using the 
whole-cell configuration with holding potential at -60 mV. Patch pipettes, pulled from 
borosilicate glass (4-6 MΩ), were filled with an internal solution containing (in mM): 
Cs-gluconate 132.5, CsCl 17.5, HEPES 10, EGTA 0.2, Mg-ATP 2 and GTP 0.3 (pH 
7.25, 290 mOsm). Synaptic responses were evoked with a concentric bipolar tungsten 
electrode located about 50 µm from the cell body layer in CA1. In some recordings, 
NMDAR-mediated EPSCs were pharmacologically isolated by supplementing our 
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aCSF with CNQX (10 µM). The AMPAR-and NMDAR-mediated EPSCs were 
measured at -70 mV and +40 mV, respectively. For NMDAR-EPSCs, the amplitude 
was measured 20 ms after the start of the stimulus artifact (von Engelhardt et al., 2010). 
Signals were amplified using multiclamp 700B, sampled at 5 kHz, and analyzed with 
Clampfit 10 software (Molecular Devices).  
Western Blotting 
For the basal protein expression and protein phosphorylation assays, 
hippocampal tissue from wild type and TRPM2 KO mice (post-natal day 20-30) was 
used for Western blot. For experiments involving quinpirole treatment, hippocampal 
slices were incubated in ECS solution bubbled with 95%O2 and 5%CO2 at room 
temperature for at least 1 h, followed by exposing to quinpirole (10 µM) or vehicle for 
30 min in aCSF. After 3 times wash with cold PBS, hippocampal tissue was 
homogenized in ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 0.1% SDS, 0.5% Triton-X100, and 1% Sodium Deoxycholate) containing 
protease and phosphatase inhibitors. These samples were subjected to SDS-PAGE, 
transferred to a nitrocellulose membrane, which was subjected to repeated probing and 
stripping with antibodies as described. The signals were quantified using VersaDoc 
Imaging System (BioRad). The antibodies PSD-95, pGSK-3βSer9, GSK-3β, GluN2A and 
GluN2B were purchased from Cell Signaling Technology, and GluR1 and GluR2 from 
Santa Cruz Biotechnology, Inc.  
 
 
Statistics  
Data are expressed as mean ± SEM. Statistical comparisons were made using 
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either unpaired t-test or one-way ANOVA followed by Bonferroni post-hoc test, 
depending on the experimental protocol.  
2.3 Results  
Hippocampal neurons were cultured from wildtype (WT) and knockout (KO) 
mice using standard procedures outlined in the methods. This allowed us to compare the 
activation of TRPM2 currents in cultured pyramidal neurons from both genotypes. 
Whole-cell voltage clamp recordings were performed with 1 mM ADPR in the patch 
solution. Under these recording conditions TRPM2 currents were absent until multiple 
voltage-ramps are used to evoke these slowly developing currents (Figure 2.1). Large 
TRPM2 inward currents were generated at a holding potential of -60 mV in neurons 
from WT mice (Figure 2.1a, c; 553.4 ± 132 pA, n = 5) but were entirely absent in those 
from KO mice (Figure 2.1b; 7.9±7.2pA, n=6; unpaired t-test, p=0.001). Importantly, no 
genotypic difference in peak Ca2+ 
 
currents were detected (3648 ± 715 pA in WT, 2836 
± 390 pA in KO; unpaired t-test, p=0.3234; Figure 2.1d). Furthermore, there were no 
changes in peak responses (or steady-state to peak ratios) to applications of NMDA 
(Figure 2.1e, f) or in the GluN2B mediated component of this response determined by 
application of 1 µM Ro-256981, a highly selective antagonist of GluN2B containing 
receptors (Figure 2.1g). These results confirm the functional identification of TRPM2 
currents in hippocampal pyramidal neurons, the absence of TRPM2 currents in neurons 
cultured from TRPM2 deficient mice, and that the absence of TRPM2 does not alter 
either voltage-dependent or NMDAR-dependent Ca2+ currents.  
Next, acute transverse hippocampal slices were prepared from TRPM2
 
KO and 
WT mice at 3-4 weeks of age using standard approaches described in the methods. Field 
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excitatory postsynaptic potentials (fEPSPs) were recorded from CA3-CA1. We noted 
no difference in the paired-pulse ratios between WT and KO mice (Figure 2.2a). We 
then examined the effects of a short period of oxygen-glucose deprivation (OGD) on 
fEPSPs in slices from both genotypes. In WT slices, OGD resulted in a strong 
depression of the fEPSPs. This depression was greatly diminished in TRPM2 KO slices, 
consistent with a phenotype of a reduced responsiveness to the oxidative stress 
mediated by TRPM2 channels (Figure 2.2b). 
TRPM2 currents can be activated by NMDAR stimulation; therefore, we 
examined whether TRPM2 might contribute to NMDAR-dependent synaptic plasticity. 
We first examined the induction of long-term potentiation (LTP) using a standard 100 
Hz stimulation. No difference in LTP was observed in slices from TRPM2
-/-
mice 
(Figure 2.3a) suggesting that TRPM2 plays little or no role in this form of synaptic 
plasticity. However, NMDARs are also required for one form of long-term depression 
(LTD) at these synapses so we extended our studies to include low frequency 
stimulation. Applying 900 pulses at 1 Hz induced LTD in WT mice (0.84 ± 0.021, n 
=10) but failed to do so in TRPM2 KO mice (Figure 2.3b; 0.98 ± 0.025, n = 10; p = 
0.017). Acute applications of the TRPM2 blocker clotrimazole also blocked LTD 
induced using this protocol (Figure 2.3c). Clotrimazole did not inhibit the induction of 
LTP (data not shown). 
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Figure 2.1. NMDAR and Ca2+ current function is preserved in TRPM2 KO 
cultured hippocampal neurons.  
(a,b) ADPR-primed TRPM2 currents are facilitated by voltage ramps ( ± 100 mV, 1/10 
sec) in WT (a), but not in cultured neurons from TRPM2-/- mice (b); (c) Summary bar 
graph of ADPR-primed peak current amplitude in WT and TRPM2-/- neurons. 
(unpaired t-test p = 0.001, 553.4 ± 132 pA in WT, n = 5; 7.9 ± 7.2 pA in KO, n = 6);  
(d) Peak Ca2+ currents elicited by the voltage ramp protocol are not altered by 
disruption of TRPM2 channel expression; Neither NMDAR peak currents (e), nor 
NMDAR steady state to peak ratios (f) generated in response to rapid applications of 
NMDA to cultured hippocampal neurons are affected by loss of TRPM2 expression; (g) 
Representative traces and summary bar graph of GluN2B subtype NMDAR inhibition 
with Ro 25-6981. Results demonstrate that the contribution of GluN2B subtype 
receptors to total NMDAR charge transfer is unaltered in cultured TRPM2 KO 
hippocampal neurons relative to control. 
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Figure 2.2 OGD-mediated LTD is impaired in the absence of TRPM2 
(a) The response to a paired-pulse protocol is identical in hippocampal slices derived 
from TRPM2 KO mice and WT controls (n=11 per group), demonstrating that pre-
synaptic short-term plasticity is unaltered in the absence of TRPM2; (b) Transient 
oxygen-glucose deprivation (5 min OGD) causes long-lasting depression of fEPSP 
slopes in slices from WT (n = 12) but not TRPM2-/- (n = 6). 
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LTD at these synapses can also depend upon activation of group 1 mGluRs 
rather than NMDARs (Collingridge et al., 2010), we therefore examined responses to a 
bath exposure to NMDA (10 µM, 5 min) or DHPG (10 µM, 20 min) in slices of both 
genotypes. The LTD induced by DHPG was similar in WT and TRPM2 KO mice 
(Figure 2.3d; 0.85 ± 0.043, n = 6 in WT vs 0.80 ± 0.031, n = 7 in TRPM2 KO mice, 
respectively; p > 0.05). Conversely, NMDA application induced LTD in slices from 
WT (n = 6) but failed to do so in TRPM2 KO mice (Figure 2.3e; n = 6). When plasticity 
induced by a range of repetitive stimulation frequencies was examined it was clear that 
TRPM2 KO slices demonstrated a substantial impairment in NMDA-dependent LTD 
(Figure 2.3f).  
The expression of NMDAR-dependent LTD at CA3-CA1 synapses requires the 
endocytosis of AMPA Receptors (AMPARs) (Collingridge et al., 2010; Sanderson, 
Collingridge, & Fitzjohn, 2011). To determine if there was a change in the functional 
expression of AMPARs in TRPM2 KO mice we used whole cell voltage clamp 
recordings to measure the ratio of AMPAR to NMDAR mediated EPSCs. By holding 
the membrane potential at -70 and +40 mV the relative contribution of each receptor 
type was determined. This ratio was significantly reduced in TRPM2 KO (n = 10) 
neurons compared to WT (n = 10, p < 0.01; Figure 2.4a). These results suggest that a 
reduction of synaptic AMPARs or alternatively an enhancement of NMDARs may 
underlie the deficiency of LTD in TRPM2 KO mice. A change in AMPARs was 
supported by our observation of a reduction of mEPSC amplitude but not frequency in 
TRPM2 KO mice (Figure 2.4b,c,d).  
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Figure 2.3 LTD is impaired in hippocampal slices derived from TRPM2 KO mice. 
(a) LTP is unaffected by knockout of TRPM2 (WT, n = 6; TRPM2-/-, n = 8); (b) LTD 
of fEPSPs evoked by repetitive stimulation (900 stimuli at 1 Hz) in WT slices (n = 10) 
is absent in slices from TRPM2 KO mice (n = 10); (c) LTD of fEPSPs was inhibited by 
application of clotrimazole, a TRPM2 inhibitor. Timing of clotrimazole application in 
treated slices is indicated by the black bar. (d) Metabotropic-glutamate receptor 
dependent LTD is unimpaired by deletion of TRPM2 (WT, n = 6; TRPM2 KO, n = 7); 
(e) Chem-LTD, evoked by 5 min application of NMDA (10 µM) is abolished in slices 
from TRPM2 KO (n = 6) but not WT (n = 6) slices; (f) Summary graph for a series of 
recordings from WT and TRPM2 KO slices in which plasticity was induced by 
repetitive stimulation delivered at 1, 10, 20, 50 Hz (900 pulses at each frequency) or 
100 Hz (four 1 sec trains delivered 20 sec apart). For each induction frequency, 
normalized fEPSP slopes, measured at the end of recording from each of the two 
populations of slices, are plotted. Numbers in parentheses represents the number of 
recordings at each point. *denotes p = 0.016. 
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We also examined the relative contribution of NMDARs composed of GluN2A 
or GluN2B subunits to synaptic currents by measuring EPSC NMDAR before and after 
application of the selective GluN2B antagonist, Ro-256981. The relative block was the 
same regardless of genotype (Figure 2.4e). 
During LTD there is some loss of postsynaptic density 95 protein (PSD-95) 
from the synapses followed by endocytosis of AMPAR (Bhattacharyya et al., 2009). 
Therefore, we used western blotting to examine if there was a change in PSD-95 
expression in TRPM2
 
KO mice. Consistent with the change in AMPARs, we observed a 
significant reduction in PSD-95 expression (Figure 2.5a). Previous reports link the level 
of PSD-95 expression with AMPAR number without an overall change in synaptic 
number (Bhattacharyya et al., 2009; Chen et al., 2011). We examined the total 
expression of GluR1 in TRPM2
 
KO slices versus those from WT mice, and as 
anticipated observed a reduction in the expression of GluR1 (Figure 2.5b). In contrast, 
the expression levels of GluR2 and NMDAR subunits were the same regardless of 
genotype (Figure 2.5b,c,).  
To further explore the mechanism of the loss of NMDAR-dependent LTD in 
TRPM2
 
KO mice we examined the activity of glycogen synthase kinase-3β (GSK-3β), 
which is required for this form of LTD (Peineau et al., 2007; Peineau et al., 2009). We 
compared the expression levels and phosphorylation of this kinase at Ser9, which is 
indicative of inactivation of GSK-3β (Frame, Cohen, & Biondi, 2001). Expression of 
GSK-3β was unaltered; however, there was an increase in Ser9 phosphorylation (GSK-
3β inactivation) in TRPM2 KO slices (Figure 2.5d) suggesting that impaired LTD in 
TRPM2
 
KO mice results from inhibition of GSK-3β (Peineau et al., 2007).  
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Figure 2.4. AMPA/NMDA Receptor Contribution to EPSCs, and mEPSC 
amplitude are diminished in TRPM2 KO slices. 
(a) The ratio of AMPAR- to NMDAR-mediated EPSCs is reduced in TRPM2-/- 
neurons. (b,c,d) Representative mEPSC traces (b) and summary bar graphs 
demonstrating that the amplitude (c), but not the frequency (d) of mEPSCs is reduced in 
slices from TRPM2 KO mice; (e) The relative contribution of GluN2B NMDAR 
subtype to NMDAR EPSC, quantified by application of the selective antagonist Ro 25-
6981, is unaltered in TRPM2 KO slices, confirming previous results in culture. 
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Insulin also acts via stimulation of Akt/PKB to inactivate GSK-3β via Ser9 
phosphorylation, resulting in a long lasting depression of AMPAR-mediated synaptic 
transmission, which in turn occludes low frequency induced LTD (Man et al., 2000). 
We therefore examined the effect of insulin on WT and TRPM2
 
KO slices. The long-
lasting depression induced by applications of insulin was lacking in TRPM2
 
KO slices 
(Figure 2.5e) suggesting that insulin-induced LTD was occluded in this genotype due to 
the pre-existing inactivation of GSK-3β. To determine if the loss of LTD in TRPM2
 
KO 
is attributable to the consistent inhibition of GSK-3β we applied the D2 agonist 
quinpirole in order to stimulate Akt GSK-3β signaling (Beaulieu, Gainetdinov, & 
Caron, 2007) and observed an enhanced activation of GSK-3β (Figure 2.5f) and rescue 
of LTD in TRPM2 KO mice (Figure 2.5g).  
 
2.4 Discussion  
Our results show that loss of TRPM2 expression modifies NMDAR-dependent 
synaptic plasticity, specifically LTD, but they do not implicate TRPM2 channels 
directly in excitatory synaptic transmission. Instead, the presence of TRPM2 channels 
seems to be associated with maintenance of the appropriate level of GSK-3β activation 
as well as full expression of PSD-95 and AMPARs. In the absence of the TRPM2 
expression there is a reduction in the relative contribution of AMPA receptors to 
synaptic transmission at CA1 synapses along with a reduction of LTD and a shift to 
lower thresholds for the induction of LTP. This metaplastic shift towards LTP in 
TRPM2 KO slices seems to result from enhanced phosphorylation and inactivation of 
GSK-3β.  
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Figure 2.5 Inhibition of GSK-3β phosphorylation and reduced PSD-95 and 
AMPAR expression contributes to impaired LTD in TRPM2 KO mice.  
The expression of (a) PSD-95 (normalized to β-actin loading control) and (b) the 
AMPAR subunit, GluR1, is depressed in slices from TRPM2 KO mice. (b,c) Expression 
of the AMPAR subunit, GluR2, and the NMDAR subunits GluN2A, GluN2B, and 
GluN1 are unchanged in the absence of TRPM2; (d) Knockout of TRPM2 is correlated 
with an increase in GSK-3β phosphorylation at its inhibitory site (Ser9, n = 3); (e) 
Insulin application to hippocampal slices depresses AMPAR-mediated fEPSPs in slices 
from TRPM2 KO, but not WT, slices. (f) Simulation of dopamine D2 receptors by 
quinpirole (10 µM) reduces GSK-3β phosphorylation at Ser9 (n = 3); (g) D2 receptor 
stimulation by quinpirole rescues LTD in slices from TRPM2 KO mice.  
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The resulting inactivation of GSK-3β prevented further depression of synaptic 
transmission by applications of insulin. Importantly, applications of quinpirole reduced 
GSK-3β phosphorylation in TRPM2 KO slices and effectively rescued LTD induction 
by repetitive low-frequency stimulation. Moreover, acute block of TRPM2 function by 
clotrimazole prevented LTD induction thereby mimicking TRPM2 loss of function by 
genetic deletion. Collectively, these findings argue that the reductions in GSK-3β 
activity, PSD-95 and GluR1 expression, as well as AMPAR-mediated synaptic 
transmission and plasticity observed in hippocampal slices derived from TRPM2
 
KO 
mice cannot simply be attributed to developmental compensations resulting from 
genetic deletion of TRPM2. Rather, in light of our findings, we propose that ongoing 
TRPM2 channel activity contributes to the regulation of AMPAR-mediated fast 
excitatory synaptic transmission through maintenance of constitutive GSK-3β activity.  
The precise mechanism through which TRPM2 activity regulates GSK-3β 
remains to be determined; however the contribution of TRPM2 to Ca2+ signaling is 
likely to play an important role is this regard. Previous findings have proposed the Ca2+
 
dependent phosphatase, calcineurin (or PP2B), as a candidate for mediating depho-
sphorylation of GSK-3β at Ser9 (Y. Kim et al., 2009). Alternatively, the Ca2+- 
dependent tyrosine kinase Pyk2 has been shown to associate and regulate GSK-3β 
activity through tyrosine phosphorylation (Sayas et al., 2006). Whether the activity of 
either calcineurin, Pyk2, or other kinases or phosphatases are altered by TRPM2-
initiated Ca2+
 
signaling remains to be established. Similarly, the behavioural 
consequence of altered synaptic transmission and plasticity associated with the loss of 
TRPM2 function has yet to be investigated; however, a recent paper by Kim and 
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colleagues (2011) may offer some insight. These authors demonstrated that behavioural 
flexibility, evaluated by reversal learning in the Morris water maze and by the delayed 
non-match to place T-maze task, was reduced following genetic disruption of PI3Kγ, 
which also resulted in a selective loss of NMDAR dependent LTD (J. I. Kim et al., 
2011). Additional research is required to assess whether these behaviours are similarly 
altered in TRPM2
 
KO mice. 
 
Conclusions  
The present study establishes that loss of TRPM2 function through genetic 
means provokes long lasting changes in excitatory synaptic transmission and plasticity 
at the CA3-CA1 hippocampal synapse. Specifically, we show that the ability to induce 
NMDAR-dependent LTD is impaired in TRPM2 KO mice. Such impairment was 
associated with increased phosphorylation and inactivation of GSK-3β. Consistent with 
previously reported changes associated with GSK-3β inhibition, we report reduced 
PSD-95 and GluR1 expression and identify a corresponding reduction in AMPAR-
mediated synaptic transmission. Interestingly, both GSK-3β and TRPM2 channels have 
been implicated in a number of overlapping pathophysiological processes ranging from 
pancreatic insulin secretion to Alzheimer’s disease (Bhat, Budd Haeberlein, & Avila, 
2004; Takahashi et al., 2011). Accordingly, our results show the importance of continu-
ing studies to determine the pathophysiological roles of GSK-3β and TRPM2 in 
neurodegenerative diseases (Jo et al., 2011).  
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3. Loss of glutathione homeostasis associated with neuronal senescence facilitates 
TRPM2 channel activation in cultured hippocampal pyramidal neurons 
 
3.1 Introduction  
Aging is a major risk factor for developing several neurodegenerative diseases. 
Although the precise reasons are poorly understood, a growing body of evidence 
suggests that age-related cognitive decline is associated with stereotypic changes in 
cellular homeostasis which ultimately lead to impaired neuronal function (Thibault, 
Gant, & Landfield, 2007). A leading hypothesis suggests that increased oxidative stress 
associated with aging predisposes neurons to dysregulated intracellular calcium (Ca2+)
 
homeostasis in response to disease causing factors (Camandola & Mattson, 2011). 
Accordingly, understanding the relation between oxidative stress and altered Ca2+ 
homeostasis may provide valuable insight into mechanisms underlying 
neurodegenerative disease. Glutathione (GSH), the most abundant intracellular reducing 
agent (Cooper & Kristal, 1997), plays an important role in limiting cellular damage by 
reactive oxygen and nitrogen species generated as a by-product of aerobic metabolism. 
Cellular levels of GSH are known to decrease with age (Chen, Richie, & Lang, 1989; 
Liu, 2002; Parihar, Kunz, & Brewer, 2008; Rebrin, Forster, & Sohal, 2007; Sasaki et 
al., 2001) and the resulting decline in antioxidant defence is viewed as a risk factor 
contributing to the increased susceptibility to neurodegenerative disease associated with 
aging. For example, a strong relationship has been demonstrated between reduced levels 
of GSH and Parkinson’s disease (M. F. Anderson & Sims, 2002; Bragin et al., 2010; 
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Martin & Teismann, 2009; Perry, Godin, & Hansen, 1982; Rehncrona & Siesjo, 1979; 
Sian et al., 1994). Furthermore, a reduction in glutathione has also been associated with 
cerebral ischemia (M. F. Anderson & Sims, 2002; Bragin et al., 2010; Rehncrona & 
Siesjo, 1979; Salemi et al., 2009). Importantly, depletion of GSH itself leads to 
increased oxidative stress, altered Ca2+
 
homeostasis and increased neuronal cell death 
(de Bernardo et al., 2004; Khanna et al., 2003; Naziroglu et al., 2011; Wullner et al., 
1999). It is unknown whether depletion of GSH promotes Ca2+ dysregulation directly 
(e.g. by altering Ca2+ permeation pathways) or through the induction of oxidative stress.  
TRPM2 is a highly unique calcium permeable non-selective cation channel that 
is responsive to reactive oxygen and nitrogen species (ROS/RNS). Channel activation 
by ROS/RNS is proposed to occur following the generation of adenosine diphosphate 
ribose (ADPR), which serves as an intracellular agonist (Sumoza-Toledo & Penner, 
2011). Notably, gating is also greatly facilitated by elevated concentrations of 
intracellular Ca2+ (McHugh et al., 2003; Olah et al., 2009). TRPM2 expression is 
highest within the brain (Fonfria et al., 2006) and recent work in our lab demonstrated 
that TRPM2 is expressed and functional in pyramidal neurons of the hippocampus 
(Olah et al., 2009), a subset of neurons that are particularly susceptible to oxidative 
stress-induced damage in stroke and neurodegenerative disease (Mattson, Guthrie, & 
Kater, 1989; X. Wang & Michaelis, 2010). This current was absent in primary 
hippocampal neurons cultured from TRPM2 knockout (KO) animals (Xie et al., 2011). 
Importantly, TRPM2 has been shown to contribute to cell death in response to 
oxidative stress, TNFα, amyloid-β peptide, and ischemia (Fonfria et al., 2005; Jia et al., 
2011; Takahashi et al., 2011). These findings raise the possibility that TRPM2 may 
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play an important role in neurological diseases associated with aging, excitotoxicity 
and oxidative stress.  
Recent evidence suggests that TRPM2 channels may be directly regulated by 
GSH. Indeed, GSH has been shown to inhibit TRPM2 currents in astrocytes, 
microglia, and dorsal root ganglion sensory neurons (Lee et al., 2010; Naziroglu et al., 
2011). Importantly, these papers did not investigate the effects of glutathione on 
TRPM2 channels in neurons susceptible to degeneration. Furthermore, the mechanism 
responsible for the observed inhibition was not explored.  
We now extend previous findings demonstrating GSH-mediated inhibition of 
TRPM2 currents by demonstrating that intrinsic, age-dependent, variations in the 
intracellular concentration of GSH is a key determinant in dictating the level of 
TRPM2 activation in neurons. Moreover, we demonstrate that the inhibition of 
TRPM2 function by GSH operates independently of its capacity as a reducing agent. 
These findings suggest that altered intracellular Ca2+ dynamics associated with GSH 
depletion, induced experimentally or with aging, may develop as a result of altered 
TRPM2 regulation.  
 
3.2 Methods  
Reagents  
Trypsin-EDTA, 5-fluorodeoxyuridine, uridine, CsOH, Gluconic acid, MgCl2, 
CaCl2, BaCl2, EGTA, KCl, Mg-ATP, N-methyl-D-aspartate (NMDA), D-serine, 
Glucose, Glutathione (GSH), L-Buthionine sulfoximine (L-BSO), and N-acetyl-cysteine 
(NAC) were all purchased from Sigma (Oakville, Ontario, Canada). HEPES and NaCl 
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were purchased from Bioshop (Burlington, Ontario, Canada). Ophthalmic acid was 
obtained from Bachem (Bubendorf, Switzerland).  
Cell culture  
Mouse hippocampal primary neuronal cultures were prepared from CD-1 
mice (Charles River, Wilmington, MA, USA) at E17-19 as described previously 
with minor adjustments (MacDonald, Mody, & Salter, 1989). Briefly, hippocampal 
tissue from embryonic day 17-18 mice were dissected, enzymatically and 
mechanically dissociation with 0.05% Trypsin-EDTA, and plated at a density of < 1 
× 10
6 
cells ml
−1 
on collagen coated Nunc™ 35 mm culture dishes (Fisher, 
Rochester, NY). After 3-5 days, each plate was treated for 24hours with 0.08 mM 5-
fluorodeoxyuridine and 0.2 mM uridine. Cells were maintained for 4 weeks in 
culture.  
Whole-cell recordings: Primary culture  
Currents were recorded from mouse hippocampal primary neuronal cultures at 
14-28 days in vitro. Whole-cell voltage-clamp recordings were performed as described 
previously, with minor adjustments (Olah et al., 2009). Unless otherwise indicated, 
standard intracellular solution (ICS) contained (in mM): 150 cesium gluconate, 10 
Hepes, and 2 MgCl2 and 1 ADPR. Standard extracellular solution (ECS) contained (in 
mM): 140 NaCl, 5.4 KCl, 25 Hepes, 33 glucose, 2 CaCl2, and 0.2 TTX. TRPM2 
currents were generated with either repeated NMDAR activation or voltage ramps. 
NMDA currents were elicited with 100 µM NMDA and 3 µM d-serine added to the 
standard ECS and applied for 5 or 10 seconds every minute using a multibarrelled rapid 
perfusion system (SF-77B; Warner Instruments, Hamden, CT, USA). Voltage ramps 
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(±100 mV, 1/10 sec) were applied in the presence of standard ECS supplemented with 1 
mM MgCl2 and 1 mM BaCl2. After the TRPM2 current stabilized, or after 10 minutes 
of recording, calcium free solution was applied (total divalent concentration was 
maintained by replacing CaCl2 with equimolar BaCl2). Data were filtered at 2 kHz, 
digitized, and acquired using pCLAMP and Axoscope software (Molecular Devices, 
Sunnyvale, CA, USA). 
Whole-cell recordings: TRPM2-HEK293  
HEK293 cells stably expressing an inducible flag-tagged human TRPM2 
(TRPM2-HEK293) were generously provided by Dr. A. M. Sharenberg (University of 
Washington, Seattle, Washington). Cells were cultured at 37°C with 5% CO2 in 
DMEM (Sigma) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin (Invitrogen, Burlington, ON, Canada). TRPM2 expression was 
induced with doxycycline (1 µg ml-1) 24 hours prior to experiments. Intracellular 
solution (ICS) contained (in mM): 130 CsGluconate, 10 HEPES, 2 MgCl2, 1 CaCl2, 10 
EGTA, and 4 Mg-ATP. ICS was adjusted to a pH of 7.3 and osmolarity between 295 
and 300 mOsm. The final resistance of ICS-filled electrodes was between 3 and 5 MΩ. 
The standard extracellular solution (ECS) was composed of (in mM): 140 NaCl, 5.4 
KCl, 25 HEPES, 33 glucose, 1 MgCl2, 2 CaCl2, pH of 7.4 and osmolarity between 310 
and 315 mOsm. Calcium-free ECS contained 2 mM BaCl2 in the place of CaCl2. Data 
were filtered at 2 kHz, digitized, and acquired using pCLAMP and Axoscope software 
(Molecular Devices). TRPM2-HEK293 cells were held at -60 mV during whole-cell 
voltage-clamp recordings. Currents were evoked through the intracellular application of 
ADPR at a concentration of 0.1 mM unless otherwise indicated. Calcium containing 
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ECS was applied for 5 minutes or until a current of -1000pA developed, followed by 2-
3 minutes in calcium-free ECS. Calcium solution was then applied until the TRPM2 
current began to inactivate, and the amplitude of the TRPM2 current was then 
determined after removal of extracellular Ca2+.  
Real-time quantitative polymerase chain reaction (QRT-PCR)  
Total RNA was extracted from primary mouse hippocampal cultures at 15, 22, 
and 29 days in vitro (DIV) with Trizol™ (Invitrogen, Burlington, Canada) according to 
the manufacturer’s protocol. RNA concentration was quantified using the Nanodrop 
Spectrophotometer ND1000 (Nanodrop technologies Inc., Wilmington, DE, USA). The 
OD260/280 ratio for all samples was greater than 1.7. Following quantification, RNA 
was reverse transcribed using Superscript™ II RT reagent according to the 
manufacturer’s guidelines, including the optional treatment with 40 units of 
RNaseOUT™ (Invitrogen). “No RT” controls contained 1 µL H2O instead of 
Superscript™ II RT reagent. The reaction was carried out in an Eppendorf  
Mastercycler personal (Hamburg, Germany).  
Primers were designed against the mouse TRPM2 coding strand (accession 
number NM_138301) and purchased from Sigma. To test primer efficiency, a 
standard curve was constructed from mouse hippocampal total cDNA using 10x 
serial dilutions, ranging from 100 ng to 0.1 ng. Inclusion criteria for primers were 
an efficiency of 90-110%, and an R
2 
value >0.98.  
To quantify TRPM2 mRNA, 100 ng of cDNA from each sample was run in 
duplicate with iQ™ SYBR green Supermix (Biorad, Mississauga, Ontario) according to 
the manufacturer’s instructions. The BioRad MyiQTM iCycler was used for real-time 
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qPCR. Negative controls included the No RT samples from reverse transcription and a 
no-template control containing water instead of cDNA. Biorad MyIQ™ 2.0 software 
was used for quantification of cycle threshold. TRPM2 primers produced a 90 bp 
amplicon using the sense sequence 5’TGATCCTGATGGCTGTGGAC3’ in 
combination with antisense sequence 5’AAGAGCAGAATGGCCCCA3’. The reaction 
was carried out at 95°C for 3minutes, followed by 40 cycles of 95°C for 1 minute and 
55°C for 30 seconds. To control for potential variation in the number of neurons present 
in culture, cycle thresholds for TRPM2 mRNA were normalized to neuron specific 
enolase (ENO2) using the sense primer sequence 5’CTGCCTCTGAGTTTTACCGC3’ 
and the antisense primer sequence 5’TCCGGACAAAGTCCTGGTAG3’. ENO2 was 
quantified with a thermal profile of 95°C for 3 minutes, followed by 40 cycles of 95°C 
for 1 minute and 62°C for 30 seconds. A dissociation curve was run for both primers 
using the following thermal profile: 95°C for 1 minute, 55°C for 1 minute, followed by 
a 2°C steps every 10 seconds from 70°C to 95°C. 
Statistics 
Data are expressed as mean ± SEM. Statistical analysis was undertaken 
using GraphPad Prism® (GraphPad Software, San Diego, CA). An unpaired two-
tailed t-test, a one-way ANOVA followed by a Tukey’s HSD post-hoc test, or a 
two-way ANOVA followed by Bonferroni post-hoc test was used to assess 
statistical significance. Data was considered significant when p < 0.05.  
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3.3 Results 
TRPM2 currents increase with time in vitro  
Primary neuronal cultures are often used to examine neuronal development; 
however, beyond 21 days in vitro, early neuronal markers such as nestin drastically 
diminishes in expression, and mature neuronal markers such as MAP-2 are expressed, 
indicative of a mature neuronal population (Bertrand et al., 2011). Furthermore, cultures 
maintained beyond 3 weeks in vitro recapitulate many of the characteristic cellular 
changes that have been associated with aging and neurodegeneration (Aksenova et al., 
1999; Bertrand et al., 2011; Kim et al., 2007; Lesuisse & Martin, 2002). These include 
increased oxidative stress, lipid peroxidation, protein tyrosine nitration, mitochondrial 
injury, ER stress, DNA damage, Ca2+
 
dysregulation, calpain cleavage, endogenous Aβ 
accumulation, and susceptibility to neuronal cell death.  
Importantly, in primary neuronal cultures the concentration of GSH has also 
been shown to decrease with time in vitro (Keelan et al., 2001; Sagara, Miura, & 
Bannai, 1993). Accordingly, long-term neuronal cultures serve as a valuable model 
system for the study of cellular changes associated with neuronal aging and 
senescence. With this in mind, we first sought to determine whether in vitro neuronal 
senescence correlates with altered TRPM2 function.  
To rigorously examine TRPM2 function over time in culture, whole-cell 
voltage-clamp recordings were made from primary hippocampal neuronal cultures 
maintained in vitro for up to 28 days. Using a previously established protocol (Olah et 
al., 2009), TRPM2 currents were evoked by intracellular administration of ADPR 
paired with repeated N-methyl-D-aspartate receptor (NMDAR) stimulation. 
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Importantly, the currents generated using this protocol can be entirely attributed to 
TRPM2 channels as they are abolished by known blockers of TRPM2 (Olah et al., 
2009). To ensure that the full complement of TRPM2 channels expressed at various 
time points are being activated in our recordings, a saturating concentration of ADPR (1 
mM) was included in the patch pipette. Furthermore, as the neuronal cell surface area 
increases over time due to the continued extension of neuronal processes, TRPM2 
currents were normalized to membrane capacitance, measurement of which correlates 
with cell surface area (p < 0.05, data not shown). As illustrated by the representative 
traces shown in Figure 3.1A and 2.1B, repeated applications of NMDA to pyramidal 
neurons loaded with ADPR caused the progressive development of large inward 
currents, the amplitudes of which stabilized within approximately 5-15 min. The 
amplitude of TRPM2 currents was then determined after removal of extracellular Ca2+, 
a protocol known to abolish TRPM2-mediated currents (Olah et al., 2009; Xie et al., 
2011). Recordings were made from neurons at 14, 20, and 26 days in vitro (DIV, n = 
5/group). Results demonstrate that there is an increase in TRPM2 current density 
between 14 and 26 DIV in cultured hippocampal pyramidal neurons (Figure 3.1C, p < 
0.05). Since activation of the NMDAR was used to elicit the TRPM2 current, we also 
analyzed whether the NMDAR current density is increased over time in vitro. No 
change was observed over this same time period (p = 0.76, Figure 3.1D). Furthermore, 
we assessed whether a change in NMDAR kinetics may explain the enhanced TRPM2 
response by calculating the integral under the NMDAR application and normalized this 
measurement to capacitance (Q/pF). Similarly, no change was observed from 2 – 4 
weeks in vitro (data not shown, p = 0.39).  
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Figure 3.1. TRPM2 currents are enhanced in hippocampal pyramidal neurons 
with time in vitro. With 1 mM ADPR included in the patch pipette, TRPM2 currents 
developed slowly following repeated (1/60 sec) applications of NMDA (100 µM, for 5 
sec). TRPM2 currents were quantified by removing extracellular calcium and amplitude 
was normalized to cell capacitance. NMDA applications are indicated with solid lines. 
Calcium-free application is depicted as a dashed line (A) Representative trace of 
TRPM2 currents recorded at 14 DIV (B) Representative trace of TRPM2 currents 
recorded at 25 DIV. (C) Current density at 14, 20 , and 26 DIV (n = 5 per group) were 
compared by one-way ANOVA followed by post-hoc Tukey`s test. A significant 
increase in TRPM2 current density between 14 and 26 DIV was observed (p < 0.05). 
(D) NMDAR current density is not significantly increased over time in vitro (p = 0.76). 
  
86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
 
TRPM2 mRNA does not change with time in vitro  
Increased TRPM2 current density with time in vitro could be attributed to an 
increase in the function of TRPM2, potentially via a decrease in glutathione, or 
alternatively an increase in TRPM2 expression. Using real-time quantitative PCR (RT-
QPCR), we tested whether TRPM2 mRNA increases with time in vitro in primary 
hippocampal cell culture. Total RNA from cells at 15 (n = 9), 22 (n = 8), and 29 (n = 9) 
DIV were run in duplicate and TRPM2 levels were quantified.  
Results were normalized to neuron-specific enolase (Eno2) by calculating delta 
cycle threshold (∆CT) values for each sample (NSE CT – TRPM2 CT) in order to 
control for any variability in neuronal content over time. Analysis by one-way ANOVA 
revealed no change in the TRPM2 cycle threshold (p = 0.89, Figure 3.2A), Eno2 (p = 
0.9, Figure 3.2B) or normalized TRPM2 mRNA levels over time in vitro (p = 0.51, 
Figure 3.2C). These findings demonstrate that changes in mRNA expression levels are 
not responsible for the increase in TRPM2 current density observed over time in vitro.  
 
Modulation of GSH alters TRPM2 currents in hippocampal pyramidal neurons  
If decreased cellular GSH content is responsible for elevated TRPM2 function 
over time in vitro, then enhancing intracellular GSH levels should diminish TRPM2 
current amplitude in older cultured neurons (~28 DIV). Conversely, reducing 
intracellular GSH levels should facilitate TRPM2 channel function in younger 
neuronal cultures (~14 DIV). 
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Figure 3.2. TRPM2 mRNA levels do not change in hippocampal primary cultures 
with time in vitro. (A) TRPM2 mRNA was measured at 14, 21, and 29 DIV (n=8 per 
group) by quantitative real-time PCR (qPCR). No significant change in cycle threshold 
values is observed (p = 0.89) (B) QPCR analysis of neuron specific enolase (ENO2) 
mRNA values used to control for neuronal content over time. No significant difference 
was observed (p = 0.9). (C) Normalized TRPM2 values for each sample (ENO2-
TRPM2) were quantified. No difference in the normalized levels of TRPM2 mRNA is 
seen over time in culture (p = 0.51). 
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We first examined the consequence of elevating the intracellular concentration 
of GSH in neurons at 4 weeks in vitro by exogenous application through the patch 
pipette. When compared with controls, GSH (10 mM) significantly inhibited TRPM2 
currents activated in the presence of ADPR by the NMDAR stimulation protocol 
(Figure 3.3A, p = 0.04). In millimolar concentrations, extracellular GSH has been 
shown to enhance NMDAR function (Kohr et al., 1994; Oja et al., 2000). No difference 
in NMDAR amplitude was observed with intracellular delivery of GSH (p = 0.82, data 
not shown). Representative traces are shown in Figure 3.3B (control) and C (10mM 
GSH). To confirm the effects of GSH on TRPM2 currents, we also examined the effects 
of GSH delivered through the patch pipette on TRPM2 currents generated by a voltage 
ramp protocol. Using this alternative protocol, GSH similarly inhibited TRPM2 currents 
(Figure 3.3D, p = 0.01). Examples of representative traces for control and GSH voltage 
ramp recordings are shown in Figure 3.3E and 2.3F, respectively.  
We next sought evidence that augmenting endogenous GSH content can 
similarly decrease TRPM2 function. We chronically treated neurons from 1-4 weeks in 
vitro with N-acetylcysteine (NAC), a precursor to GSH that has been shown to increase 
levels of endogenous GSH (M. F. Anderson & Sims, 2002; Aoyama, Watabe, & 
Nakaki, 2008; Gao et al., 2009; Jayalakshmi et al., 2005) and examined whether 
TRPM2 currents in cultures at 4 weeks in vitro were reduced. Treatment with 50 µM 
NAC beginning at 1 week in vitro significantly attenuated TRPM2 currents in cultures 
at 28 DIV (p= 0.04, Figure 3.4A-C). Previous studies have shown that NAC is able to 
act as a reactive oxygen scavenger independent of its ability to upregulate GSH 
(Aruoma et al., 1989).  
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Figure 3.3. GSH inhibits TRPM2 currents in hippocampal pyramidal neurons.  
(A) 10 mM GSH in the patch pipette significantly inhibits TRPM2 currents generated 
by 1 mM ADPR with an NMDAR stimulation protocol (p = 0.04). (B, C) 
Representative traces of control and GSH inhibition with the NMDAR stimulation 
protocol. (D) 10 mM GSH in the patch pipette significantly inhibits TRPM2 currents 
generated by 1 mM ADPR with a voltage ramp protocol (p = 0.01). (E,F) 
Representative traces of control and GSH inhibition with the voltage ramp protocol 
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To confirm that the observed effect can be attributed to GSH and not to NAC itself, 
NAC (50 µM) was included in the patch pipette and TRPM2 currents were elicited with 
the NMDA activation protocol with 1 mM ADPR in the patch pipette. Compared to 
controls (1076 ± 204.9, n = 3), acute NAC (910.5 ± 142.8 n = 4) did not alter TRPM2 
currents (p= 0.52, data not shown). These results confirm previous findings that GSH 
can inhibit TRPM2 currents, and are consistent with the notion that reduced GSH, at 
least in part, may underlie the increase in TRPM2 currents that we observed in 
hippocampal pyramidal neurons over time in vitro. These findings also imply that GSH 
constitutively suppresses TRPM2 function in younger cultured neurons.  
Accordingly, we next examined whether depleting GSH could augment TRPM2 
function in young cultures maintained for 2 weeks in vitro. L-buthionine-(S,R)-
sulfoximine (L-BSO) inhibits the enzyme γ-glutamylcysteine synthetase, the rate 
limiting step in GSH synthesis (M. E. Anderson, 1998) and is effective in depleting 
GSH (M. F. Anderson & Sims, 2002; Aoyama et al., 2008; Keelan et al., 2001; Sebastia 
et al., 2003; Wullner et al., 1999). Consistent with our hypothesis, TRPM2 currents 
were significantly potentiated, when compared with controls (p= 0.01), in 2 week old 
cultured neurons depleted of GSH by treatment with 250 µM L-BSO for 48 hours 
(Figure 3.4D-F).  
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Figure 3.4. Modulation of Endogenous GSH Alters TRPM2 Currents  
(A)  Treatment from 1-4 weeks in vitro with 50 µM NAC significantly inhibited 
TRPM2 currents generated by 0.3 mM ADPR and an NMDAR stimulation protocol in 
cultures at 28 DIV (p= 0.04). (B, C) Representative control and NAC traces. (D) A 48 
hour treatment with 250 µM L-BSO significantly enhances TRPM2 currents generated 
with 1 mM ADPR with an NMDAR stimulation protocol in hippocampal pyramidal 
neurons at 2 weeks in vitro. (E, F) Representative control and L-BSO traces. 
95 
 
 
 
96 
 
 
Mechanism of TRPM2 inhibition by GSH  
HEK293 cells stably expressing TRPM2 under control of an inducible 
promoter (TRPM2-HEK293) were used to characterize the mechanism of GSH-
mediated TRPM2 inhibition. To further validate our findings in hippocampal 
pyramidal neurons, and previous findings in glial and dorsal root ganglion cells 
[20,31], TRPM2 currents from TRPM2-HEK293 cells were recorded in the whole-cell 
patch clamp configuration with 0.1 mM ADPR in the patch pipette. Of note, HEK293 
cells do not express NMDARs nor voltage-gated Ca2+
 
channels. In these cells, 
intracellular application of ADPR alone is sufficient to activate TRPM2 channels in 
this model system, presumably due to the much higher induced channel expression. 
Currents generated under control conditions were compared to those generated when 
10 mM GSH was included in the patch pipette, and removal of extracellular Ca2+
 
was 
used to abolish the TRPM2 current. In these cells, intracellular delivery of GSH 
substantially attenuated the TRPM2 current (Figure 3.5, p < 0.001). 
GSH may regulate channel function through a number of distinct mechanisms 
including redox mechanisms, or post-translational modification involving the 
formation of mixed protein disulfides (i.e. glutathionylation). Through its reducing 
potential GSH has been shown to regulate the function of other receptors and 
channels, including NMDARs (Bodhinathan, Kumar, & Foster, 2010; Kohr et al., 
1994). To examine the possibility that TRPM2 is regulated through changes in its 
redox state, we examined whether the inhibitory effect of GSH could be mimicked by 
another reducing agent, dithiothreitol (DTT). DTT was included in the patch pipette 
and currents were recorded from TRPM2-HEK293 cells. At 10 mM DTT, no change 
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in TRPM2 amplitude was observed when compared to controls (p > 0.05; Figure 3.5), 
suggesting that the reducing ability of GSH is not responsible for the change in 
TRPM2 currents.  
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Figure 3.5. GSH inhibits TRPM2 in a thiol-independent mechanism. TRPM2 
currents were elicited in HEK293-TRPM2 cells using a 2mM calcium extracellular 
solution and 0.1mM ADPR. TRPM2 currents were then inhibited and quantified 
following removal of extracellular calcium (A) Representative TRPM2 responses 
obtained in control (n=12), GSH (n=10), DTT (n=6) and ophthalmic acid (n=6) groups 
(B) TRPM2 currents are significantly inhibited with 10 mM GSH or 10 mM ophthalmic 
acid, but are not altered when 10 mM DTT is included in the patch pipette (One-way 
ANOVA followed by post-hoc Tukey’s test, * p < 0.05). 
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GSH has also been shown to inhibit currents through direct binding to 
channels, either at thiol residues, known as glutathionylation, or at other non-thiol 
containing binding sites (Herson & Ashford, 1999; W. Wang et al., 2005; Yang et al., 
2010). Ophthalmic acid (γ-glutamyl-2-amino-n-butanoylglycine) is an analogue of 
GSH which contains L-2-aminobutyrate in place of the cysteine residue (WALEY, 
1958). This analogue lacks both the ability to form disulphide bonds and the reducing 
potential of GSH. Interestingly, when ophthalmic acid (10 mM) was included in the 
patch pipette, TRPM2 currents were significantly inhibited in TRPM2-HEK293 cells 
(p < 0.001; Figure 3.5). This demonstrates that GSH acts in a thiol-independent 
manner to inhibit TRPM2 currents. 
Potential mechanisms of TRPM2 inhibition by GSH were further studied by 
constructing a concentration-response relationship for ADPR with or without 10 mM 
GSH included in the patch pipette. TRPM2 currents were evoked with varying 
intracellular concentrations (0.03 - 3 mM) of ADPR. Each point on the curve 
represents the mean +/-SE of 6 -11 recordings (Figure 3.6). A two-way ANOVA 
followed by Bonferroni post-hoc test revealed an overall significant effect, with a 
highly significant inhibition by GSH for TRPM2 currents evoked with ADPR 
concentrations of 0.1, 0.3, and 1 mM (p < 0.001). No difference between groups was 
observed at the highest (3 mM) and lowest (0.03 mM) ADPR concentrations (p > 
0.05). In control conditions, the EC50 of ADPR was 77 µM, consistent with a previous 
report (Perraud et al., 2001). In contrast, the EC50 of ADPR with 10 mM GSH was 
269 µM, representing a ~3.5 fold change in sensitivity when GSH is included in the 
patch pipette.  
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Figure 3.6. GSH shifts the ADPR concentration-response curve of TRPM2 
channels by 3.5 fold. TRPM2 currents were generated with or without 10 mM GSH 
included in the patch pipette. Intracellular concentrations of ADPR used to evoke the 
current ranged from 0.03 – 3mM. Each point on the curve represents the mean +/- SE of 
6 – 11 recordings. Significant inhibition by GSH was observed for TRPM2 currents 
evoked by ADPR concentrations of 0.1, 0.3, and 1 mM (p<0.001), with no difference 
between groups at the highest (3 mM) and lowest (0.03 mM) ADPR concentration 
points (p>0.05). The EC50 value for ADPR was increased from 77 µM (control) to 269 
µM (10 mM GSH) in the presence of 10 mM GSH, representing a ~3.5 fold change in 
sensitivity to ADPR. Concentration-response curves were fit using a sigmoidal 
concentration-response (variable slope), with a Hill slope of 2.2 in control, and 0.9 in 
the GSH data set. 
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The concentration–response curves fit using a sigmoidal concentration–
response (variable slope), results in a Hill slope of 2.2 in control, and 0.9 in the GSH 
data set. The rightward shift in the concentration-response relationship and decrease in 
the Hill coefficient confirm that GSH inhibits TRPM2 channels. The results with DTT 
and ophthalmic acid confirm that the effects of GSH are thiol independent. However, 
whether GSH functions as a channel blocker, competes for the ADPR binding site, or 
interferes with TRPM2 currents by binding to ADPR requires further investigation.  
 
3.4 Discussion  
In this study we demonstrate that TRPM2 function increases with time in 
vitro in cultured hippocampal pyramidal neurons. Moreover, we show that by 
altering the intracellular concentration of GSH TRPM2 current amplitude can be 
modulated in this system. Specifically, this was shown in experiments where GSH 
was supplied exogenously through the patch pipette, or alternatively, where we 
modulated endogenous GSH metabolism. We also demonstrate that ophthalmic 
acid, but not DTT, is able to recapitulate GSH mediated inhibition of TRPM2 
currents, suggesting that GSH inhibits TRPM2 channels independently of its 
electron-donating capacity. Lastly, a 3.5-fold shift in the concentration-response 
curve and decrease in the Hill coefficient for ADPR generated TRPM2 currents 
suggest that GSH either disrupts the co-operative interaction between ADPR and 
TRPM2 or functions as a channel blocker. Further research is required to determine 
the precise nature of this interaction. The mechanism through which GSH inhibits 
TRPM2 and its relevance to the regulation of the channel in neurons is crucial to 
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understanding the pathways leading to neurotoxicity.  
TRPM2 is a Ca2+
 
permeable non-selective ion channel implicated in oxidative 
stress-induced cell death (Fonfria et al., 2005; Jia et al., 2011; Takahashi et al., 2011). 
Several factors have been reported to modulate TRPM2 current response including Ca2+
 
concentration, temperature, pH, phosphorylation, the epilepsy related protein EFHC1, 
and CD38 (Katano et al., 2012; Numata et al., 2012; Takahashi et al., 2011). Recently, 
TRPM2 currents were shown to be inhibited by GSH in sensory neurons (Naziroglu et 
al., 2011) as well as in glial cells, where TRPM2 activation following chemically 
induced GSH depletion contributes to neuroinflammation (Lee et al., 2010; Naziroglu et 
al., 2011). Our own findings now demonstrate that intrinsic alterations in endogenous 
GSH content are associated with altered TRPM2 function in hippocampal pyramidal 
neurons. Collectively, these studies suggest that GSH is a physiologically relevant 
regulator of TRPM2 and that dynamic changes in GSH content are likely to be 
associated with parallel changes in TRPM2 function. Importantly, a reduction in GSH 
has been associated with normal aging in vivo (Chen et al., 1989; Liu, 2002; Rebrin et 
al., 2007; Robillard et al., 2011; Sasaki et al., 2001). Neurodegenerative disorders, 
including Parkinson’s disease and progressive supranuclear palsy, are associated with 
enhanced depletion in intracellular GSH compared to age-matched controls (Martin & 
Teismann, 2009; Perry et al., 1982; Sian et al., 1994). GSH depletion is also observed 
following ischemia in animal models and in human subjects (M. F. Anderson & Sims, 
2002; Bragin et al., 2010; Rehncrona & Siesjo, 1979; Salemi et al., 2009). Diminished 
levels of reduced GSH has also been linked to bipolar disorder, major depressive 
disorder, and schizophrenia (Do et al., 2000; Gawryluk et al., 2011). Importantly, 
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upregulation of glutathione with NAC treatment protects against neuronal cell death in 
vitro and in vivo (Andreassen et al., 2000; Clark et al., 2010; Henderson et al., 1996; 
Jayalakshmi et al., 2005; Mayer & Noble, 1994; Morshead & van der Kooy, 2000; 
Rothstein et al., 1994).  
The findings in this manuscript raise the intriguing possibility that GSH 
depletion associated with aging, ischemia, and several psychiatric and 
neurodegenerative disorders, may be associated with enhanced TRPM2 channel 
function. Future experiments will be required to assess whether TRPM2 currents are 
also enhanced with age in vivo, and/or in models of neurological disease associated 
with GSH depletion. Furthermore, the contribution of TRPM2 to neurodegeneration 
and dysfunction associated with these conditions should be established. Interestingly, 
depletion of GSH in Parkinson’s is one of the earliest biochemical markers of 
impending neuronal degeneration (Martin & Teismann, 2009). Moreover, TRPM2 is 
expressed and functional in dopaminergic neurons of the substantia nigra (Chung, 
Freestone, & Lipski, 2011). Accordingly, whether TRPM2 currents are enhanced in 
models of Parkinson’s disease (or other neurodegenerative disease in which GSH is 
depleted) and whether knock-out of TRPM2 may attenuate neurodegeneration has yet 
to be investigated. Importantly, neurodegenerative diseases are well known to be 
associated with pronounced neuroinflammatory response. The demonstration that 
GSH depletion in glial cells promotes neuroinflammation through a mechanism 
involving TRPM2 (Lee et al., 2010), paired with our demonstration that GSH 
depletion facilitates TRPM2 function in vulnerable hippocampal pyramidal neurons, 
suggests that TRPM2 activation contributes to neuronal demise in neurodegenerative 
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disease through multiple mechanisms. By extension, TRPM2 may represent an 
important target for the development of novel therapeutic agents of benefit in the 
treatment of these debilitating neurological diseases.  
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4. Fyn kinase, Aβ, and TRPM2: Potential implications to Alzheimer’s Disease  
 
4.1 Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a 
prevalence of approximately 500,000 individuals in Canada, representing 1.5% of our 
total population (Alzheimer Society of Canada, 2010). AD presents with degeneration 
of the basal forebrain cholinergic neurons, entorhinal cortex, hippocampus and cortex 
(Coyle, Price, & DeLong, 1983; Gomez-Isla et al., 1996). The degree of degeneration 
and synaptic loss in these areas correlate strongly with the severity of dementia (Scheff 
& Price, 2003).  
Soluble oligomers of Aβ42 are believed to initiate the primary insult leading to 
degeneration through modulation of a variety of pathways (Hardy & Selkoe, 2002). For 
example, Aβ42 increases GSK-3β activity, which subsequently contributes to the 
pathological hyperphosphorylation of tau (Hernandez, Lucas, & Avila, 2012; Hooper, 
Killick, & Lovestone, 2008). Downregulation of endogenous tau attenuates neuronal 
cell death and behavioural deficits in a mouse model of AD, demonstrating that 
pathologically modified tau is critical for neurotoxicity in AD (Roberson et al., 2007). 
Although the mechanism through which tau contributes to neurotoxicity is still under 
investigation, recent evidence suggests that tau confers toxicity in AD, at least in part, 
by targeting the non-receptor tyrosine kinase Fyn to NMDA Receptors (NMDARs) 
(Ittner et al., 2010).  
Exposure to a high concentration of Aβ induces a series of changes at the 
cellular level including reduced excitatory synaptic transmission in the hippocampus, 
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increased levels of intracellular Ca2+, and increased neuronal death (Huang & Mucke, 
2012). Several studies have suggested that aberrant activation of NMDARs in response 
to Aβ exposure could explain these phenomena (Alberdi et al., 2010; Hu et al., 2009; 
Molnar et al., 2004; Ronicke et al., 2010). Importantly, Aβ oligomer exposure exerts a 
dichotomous effect on excitatory synaptic transmission, enhancing transmission when 
concentrations are low, and decreasing transmission when concentrations are high 
(Puzzo, Privitera, & Palmeri, 2012). High concentrations of Aβ or prolonged exposure 
have also been shown to decrease NMDAR amplitude and promote internalization of 
NMDARs (Jacob et al., 2007; Kurup et al., 2010; Snyder et al., 2005). Furthermore, 
clinical trials with the NMDAR antagonist memantine only produces a modest 
improvement in moderate to severe AD, and marginal benefit in mild to moderate AD 
(McShane, Areosa Sastre, & Minakaran, 2006). It is therefore unlikely that the tau-Fyn-
NMDAR complex can explain all of the toxicity observed in AD. 
We propose that the Ca2+ permeable non-selective cation channel TRPM2 may 
participate in this toxic protein complex. TRPM2 channels are activated by oxidative 
stress, and have been shown to contribute to cell death in a variety of cell types 
(Takahashi et al., 2011). Furthermore, the decrease in NMDAR amplitude induced by 
Aβ requires the activation of another non-NMDAR inward current which, similar to 
TRPM2, displays a linear I-V relationship (Snyder et al., 2005). Indeed, one previous 
study demonstrated that knockdown of TRPM2 protected a striatal culture system from 
cell death induced by 20µM monomeric Aβ (Fonfria et al., 2005). Although the 
relevance to AD of striatal cultures and high  concentrations of monomeric Aβ is 
questionable, this study did provide the first evidence that TRPM2 may participate in 
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AD. Furthermore, previous work in our lab has demonstrated that TRPM2 currents can 
be activated by strong stimulation of NMDARs (Olah et al., 2009). We have also 
demonstrated that TRPM2 interacts with the GluN1 subunit of NMDARs, and 
inhibition of GluN2B containing NMDAR significantly attenuates TRPM2 current 
development in cultured hippocampal neurons (M. Jackson & J. MacDonald, 
unpublished). This data suggests a unique physical and functional relationship between 
GluN2B containing NMDAR and TRPM2. We also previously demonstrated that 
TRPM2 contributes to maintaining GSK-3β activity, raising the possibility that TRPM2 
may play a role in the pathological alterations to tau (Xie et al., 2011). Lastly, a recent 
study showed that TRPM2 is phosphorylated on tyrosine residues following exposure to 
oxidative stress (Zhang et al., 2007).  The influx of Ca2+ observed after exposure to 
oxidative stress in TRPM2 expressing cells is reduced when cells are pretreated with 
PP2, an SFK inhibitor (Zhang et al., 2007).  
In humans, the SFK family consists of 9 members including Src, Fyn, Yes, Fgr, 
Lck, Hck, Blk, Lyn, Frk. In this study, we focus on Fyn as a potential modulator of 
TRPM2 function. Fyn is expressed at the post-synaptic density in neurons, and 
modulates synaptic plasticity (Husi et al., 2000; Yang, Trepanier et al., 2011). 
Furthermore, Fyn demonstrates enhanced activity and/or expression in response to 
oxidative stress (Gao et al., 2009; Griendling et al., 2000; Sanguinetti, Cao, & Corley 
Mastick, 2003). Fyn has also been shown to promote neurotoxicity in models of 
Alzheimer’s disease (Chin et al., 2004; Chin et al., 2005; Ho et al., 2005; Ittner et al., 
2010; Lambert et al., 1998). Recently, our lab demonstrated that Fyn enhances GluN2B 
containing NMDAR currents and favours long-term depression (LTD) (Yang, Trepanier 
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et al., 2011). This finding is of particular importance because we have also shown that 
TRPM2 activity is required for NMDAR-dependent LTD (Xie et al., 2011). 
 In the present study we expand upon the initial finding that TRPM2 participates 
in Aβ mediated toxicity. We hypothesize that Aβ will enhance TRPM2 currents in 
cultured hippocampal neurons. We further investigate the hypothesis that TRPM2 is 
regulated by Fyn kinase by evaluating a potential physical and functional relationship 
between Fyn and TRPM2. These results provide a novel pathway through which 
TRPM2 activity is regulated, and also implicate TRPM2 in neurodegenerative 
processes, such as AD, associated with Fyn kinase. 
 
4.2 Methods 
Cell Culture 
Mouse hippocampal primary neuronal cultures were prepared from embryonic 
day 17-18 mice. The hippocampus was dissected, enzymatically and mechanically 
dissociated with 0.05% Trypsin-EDTA, and plated at a density of < 5 × 105 cells ml−1 
on collagen coated Nunc™ 35 mm culture dishes (Fisher, Rochester, NY). Cells were 
maintained for 4 weeks in Neurobasal medium (Invitrogen, Burlington, Ontario, 
Canada), supplemented with B-27 (Invitrogen) and glucose (Sigma, Oakville, Ontario, 
Canada). 
Aβ Oligomer Preparation 
Amyloid (r-peptide, Bogart, GA, USA) was prepared according to a previously 
established protocol (Stine et al., 2003). Oligomerization of samples was confirmed by 
separation on a 16.5% Tris-Tricine gel (Biorad), transfer to a nitrocellulose membrane, 
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and detection of Aβ (Signet 6E10, 1:7000). Monomers, dimers, trimers, and tetramers 
were detectable using these oligomerization condtions (Figure 4.1). 
MTT Assay 
An MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
reduction assay was used to assess cell viability following Aβ oligomer exposure. The 
assay was conducted according to manufacturer’s protocol with minor modifications. 
Briefly, MTT reagent (Sigma) was dissolved to 5mg/mL in PBS. The solution was then 
added to the cells at a concentration 50µg/mL for 1.5hours. Media was then removed, 
and 1mL DMSO was added to the cells. Absorbance was measured at 595nM and 
650nM.  
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Figure 4.1 Amyloid Oligomers 
Oligomerization of Aβ1-42 (15µL of 10µM prepared Aβ, r-peptide) was confirmed by 
western blotting. Samples were separated on a 16.5% Tris-Tricine gel (Biorad), 
transferred to a nitrocellulose membrane, and probed for Aβ (Signet 6E10, 1:7000). 
Results indicate the presence of Aβ monomers, dimers, trimers, and tetramers. 
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Whole-Cell Recordings: Cultured Hippocampal Neurons 
Whole-cell voltage-clamp recordings were performed as described previously 
(Olah et al., 2009). TRPM2 currents were generated with either repeated NMDAR 
activation or voltage ramps. Briefly, patch electrodes were filled with an intracellular 
solution (ICS) containing: 150mM cesium gluconate, 10mM Hepes, 2mM MgCl2, with 
or without 0.3mM ADPR. Standard extracellular solution (ECS) contained 140mM 
NaCl, 5.4mM KCl, 25mM Hepes, 33mM glucose, 2mM CaCl2..  Zero calcium ECS 
contained 2mM BaCl2 in the place of CaCl2. For voltage ramp recordings, ECS was also 
supplemented with 1mM BaCl2 and 1mM MgCl2. Voltage ramps (±100mV, 1/10sec) 
were applied in the presence of Ca2+ containing ECF.. For NMDA-evoked TRPM2 
currents, NMDA currents were evoked for 5 seconds every minute with standard ECS 
supplemented with 100 µM NMDA and 3 µM d-serine, using a multibarrelled rapid 
perfusion system (SF-77B; Warner Instruments, Hamden, CT, USA). For both 
recording protocols, zero Ca2+ ECF was applied after the current was stable for at least 
1 minute. Recordings were performed at a holding potential of -60mV at room 
temperature (20–22°C) using a Multiclamp 700A amplifier (Molecular Devices, 
Sunnyvale, CA). ECS was applied with a multibarrelled perfusion system (SF-77B; 
Warner Institute, Hamden, CT, USA). Data were filtered at 2 kHz, digitized, and 
acquired using pCLAMP and Axoscope software (Molecular Devices).  
Whole-Cell Recordings: HEK293-TRPM2 Cells 
HEK293 cells stably expressing an inducible flag-tagged human TRPM2 
(HEK293-TRPM2) were generously provided by Dr. A.M. Sharenberg (University of 
Washington, Seattle, Washington). Cells were maintained in DMEM (Sigma) 
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supplemented with 10% fetal bovine serum (Invitrogen, Burlington, ON, Canada). 
Doxycycline (1µg/mL) was used to induce TRPM2 expression 24 hours prior to 
recording. ICS contained (in mM): 130 CsGluconate, 10 HEPES, 2 MgCl2, 1 CaCl2, 10 
EGTA, and 4 Mg-ATP. ICS was adjusted to a pH of 7.3 and osmolality between 295-
300 mOsm. Standard ECS as listed above omitting TTX and D-serine, and including 1 
MgCl2. Zero calcium ECS replaced the 2mM CaCl2 with BaCl2. Currents were evoked 
through intracellular application of ADPR at a concentration of 0.1mM. Calcium 
containing ECS was applied until a current of -1000 pA developed, followed by 2-3 
minutes in zero calcium ECS. TRPM2 currents were then activated in the presence of 
Ca2+ ECS until the current began to inactive. A second peak was generated following 5 
minutes in zero Ca2+ ECS. No difference in amplitude was observed between the first 
and second peak, so results presented in this report reflect data gathered from the first 
TRPM2 response generated. 
Fyn Constructs 
Wild-type Fyn Construct 
Fyn kinase (accession number NM_00237.3) was amplified from a human 
cDNA library using KOD Hot Start DNA Polymerase (EMD Biosciences, San Diego, 
CA) using primers listed in table 1 and thermal profile: 95°C for 2 minutes followed by 
10 cycles at 94°C for 15 seconds, 60°C (-1°C/cycle) for 15 seconds, and 72°C for 40 
seconds, and 25 cycles at 94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 40 
seconds. The PCR product was then run on a 1% w/v agarose gel plus 0.5µg/mL of 
ethidium bromide (Sigma-Aldrich, Oakville, Canada). PCR product was extracted from 
the agarose gel using a GenElute gel extraction kit (Sigma). A double restriction 
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enzyme digest with NotI and AscI (NEB, Ipswich, MA) was carried out at 37°C for 2 
hours, followed by purification with GenElute columns according to manufacturer’s 
protocol (Sigma). The purified product was then ligated using T4 DNA ligase (NEB) at 
a 1:5 (vector:insert) molar ratio into NotI/AscI digested pcDNA3.1. Ligated product 
was transformed into JM109 competent cells (Promega, Madison, WI, USA) and grown 
up on LB + amplicillin plates overnight at 37°C. Colonies were then expanded in LB + 
amp selection medium overnight at 37°C, and pellets were subjected to miniprep using 
the GenElute Plasmid Miniprep kit (Sigma) according to manufactuer’s protocol. Triple 
restriction digest (AscI/NotI/XhoI) was carried out to confirm incorporation of Fyn, and 
positive clones were confirmed by sequencing (London Regional Genomics Centre, 
Robarts Research Institute, London, Ontario). 
Site Directed Mutagenesis 
A constitutively active (Fyn Y531F) and dominant negative (Fyn K299M) form 
of Fyn kinase were created by site direct mutagenesis. Primers were designed to align 
with WT Fyn, replacing the lysine residue at amino acid 299 with a methionine (AAG 
 ATG) for FynK299M, and replacing tyrosine 531 with phenalalanine (TAC  TTC) 
for Fyn Y531F. Two separate PCR reactions were carried out to create fragment 1 and 
fragment 2 of FynK299M using primers listed in table 1 using the generated 
pcDNA3.1-hFyn as a template. The reaction was carried out with KOD polymerase 
(EMD Biosciences) using the following thermal profile: 95°C for 2 minutes followed by 
10 cycles at 94°C for 15 seconds, 60°C (-1°C/cycle) for 15 seconds, and 72°C for 15 
seconds, and 25 cycles at 94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 15 
seconds. Fragments 1 and 2 were then combined and the full length product was 
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generated with KOD polymerase at 95°C for 2 minutes followed by 5 cycles at 94°C for 
15 seconds, 60°C (-1°C/cycle) for 15 seconds, and 72°C for 40 seconds. The reaction as 
paused to add WT Fyn forward and reverse primers, and the PCR reaction was resumed 
with 5 cycles at 94°C for 15 seconds, 55°C (-1°C/cycle) for 15 seconds, and 72°C for 
40 seconds, and 25 cycles at 94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 40 
seconds. Y531F was generated with a single reaction using KOD polymerase, Y531F 
primers listed in table 4.1, and pcDNA3.1-hFyn as a template using the same thermal 
profile outlined for cloning WT Fyn. 
PCR product from Fyn K299M and Y531F mutagenesis was run on a 1% w/v agarose 
gel plus 0.5µg/mL of ethidium bromide (Sigma) to confirm product size.  The 
corresponding bands were cut out and extracted with the Sigma GenElute gel extraction 
kit according to protocol. A double restriction enzyme digest (NotI/AscI) followed by 
digest purification with genElute columns was completed prior to ligation of PCR 
product into pcDNA 3.1, transformation into JM109 competent cells, colony expansion 
and miniprep as described earlier. Fyn mutant incorporation was confirmed with triple 
restriction enzyme digest (AscI/NotI/XhoI), and positive clones were confirmed with 
sequencing (London Regional Genomics Centre). 
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Table 4.1. Primers used in site-directed mutagenesis 
Construct Forward Primer (5’  3’) Reverse Primer (5’  3’) 
WT Fyn TAGGCGCGCCAACCATGGG
CTGTGTGCAATGTAAGGA 
TAGCGGCCGCTTACAGGTTT
TCACCAGGTTGGTACT 
Fyn K299M-1 TAGGCGCGCCAACCATGGG
CTGTGTGCAATGTAAGGA 
GGTTTAAGAGTCATTATGGC
TACTTTTGTGTTTCC 
Fyn K299M-2 GTAGCCATAATGACTCTTA
AACCAGGCACAATG 
TAGCGGCCGCTTACAGGTTT
TCA 
Fyn Y531F ATGGCGCGCCAACCATGGG
CTGTGTGCAATGTAAGGA 
GAGCGGCCGCTTACAGGTTT
TCACCAGGTTGGAACTGGG
GCTC 
 
Transfection 
HEK-TRPM2 cells were maintained in DMEM + 10% fetal bovine serum (FBS) 
(Invitrogen). Prior to transfection, cells were plated on 100mm dishes at 30% 
confluency and induced to express TRPM2 with doxycycline (1µg/mL). The following 
day, cells were transfected with JetPRIME™ (Polyplus, Illkirch, France) according to 
the manufacturer’s instructions, using 12.5µL instead of the recommended 20-30µL 
JetPRIME reagent.  After 4 hours, media was replaced with DMEM + 10% FBS + 
1µg/mL doxycycline. Cell lysates were collected 48 hours after transfection (lysis 
buffer:  150mM NaCl, 0.1% NP-40, 2mM CaCl2, 50mM Tris-HCl (pH 7.5), 
supplemented with mini complete protease cocktail inhibitor tablet (Roche) and 1% 
Halt phosphatase inhibitor cocktail (Thermo, Rockford, IL, USA). Lysates were 
incubated on a nutating shaker for 20 minutes at 4ºC, followed by centrifugation for 30 
minutes at 16000 x g at 4ºC. Protein was then quantified from the soluble fraction by 
BCA assay (Thermo). 
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Immunoprecipitation and Western Blot Analysis 
Lysates (1mg protein) were brought up to a volume of 500µL with lysis buffer 
plus protease and phosphatase inhibitors and incubated overnight at 4ºC with 20µL 
packed monoclonal anti-Flag M2 agarose beads (Sigma). Immunoprecipitates were then 
rinsed 3x with 1mL lysis buffer, resuspended in 2x Laemmli sample buffer and heated 
for 30 minutes at 37ºC. Samples were subjected to SDS-PAGE on an 8% 
polyacrylamide gel and transferred onto a nitrocellulose membrane. Membranes were 
cut at 72kDa, and the top portion was probed with an anti-tyrosine antibody (4G10, 
1:2000, mouse IgG; Millipore Corp, Billerica, MA) followed by anti-mouse-HRP 
secondary antibody (1:5000) and detection with ECL reagent (supersignal, Pierce). The 
top portion of the membrane was then stripped and re-probed for TRPM2 using anti-
Flag-HRP (M2 clone, 1:1000; Sigma) and detected with ECL. The bottom portion of 
the gel was probed with an anti-Fyn antibody (H80, 1:500, rabbit igG; Santa Cruz 
Biotechnology, Santa Cruz, CA), followed by anti-rabbit-HRP secondary antibody 
(1:5000) and detection with ECL reagent. Blots were imaged with the VersaDoc™ 
imaging system (Biorad). 
Statistical Analysis 
Data are expressed as mean ± SEM. Statistical analysis was undertaken using 
GraphPad Prism® (GraphPad Software, San Diego, CA). An unpaired two-tailed t-test, 
one-way ANOVA followed by a Tukey’s HSD post-hoc test, or two-way ANOVA 
followed by Bonferroni post-hoc test was used to analyze data. Results were considered 
significant when p<0.05. 
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4.3 Results 
4.3.1 TRPM2 contributes to Aβ toxicity 
Our first objective was to examine neuronal viability in response to Aβ 
treatment in cultured hippocampal neurons derived from wild type (WT) or TRPM2 
knockout (KO) mice. MTT reduction was used to assess cell viability. Cultured 
hippocampal neurons at 3 weeks in vitro were treated for 24 hours with 1 µM 
oligomeric Aβ. Hippocampal neurons derived from WT cultures demonstrate a decrease 
in viability following treatment with Aβ (p<0.05, Figure 4.2). This reduction in viability 
is not observed in cultures derived from TRPM2 KO animals (p> 0.05). Importantly, a 
scrambled Aβ42 peptide control did not decrease neuronal viability measured by MTT 
assay (p>0.05, data not shown). This demonstrate that the genetic deletion of TRPM2 
protects hippocampal neurons from the loss of cell viability induced by Aβ oligomers.  
4.3.2 Aβ indirectly potentiates TRPM2 currents 
We reasoned that the decrease in cell viability occurs as a result of enhanced 
TRPM2 currents and increased intracellular Ca2+ levels. To examine this hypothesis, 
TRPM2 currents were evoked using in cultured hippocampal pyramidal neurons at 3-4 
weeks in vitro following treatment for 24 hour with either 1µM Aβ42 oligomers or 
vehicle control. TRPM2 current density was significantly enhanced following pre-
treatment with Aβ (-17.01 ± 2.13 pA/pF, n=17) relative to vehicle control (-10.64 ± 
1.03 pA/pF, n=15, p = 0.015, Figure 4.3A). Interestingly, the same effect is not 
observed with HEK293-TRPM2 cells pretreated with 1µM Aβ (-4447 ± 1680 pA, n=6) 
compared with vehicle treated controls (-5329 ± 1212 pA, n=7, p=0.67, FIGURE 4.3B), 
suggesting that Aβ does not act directly to augment TRPM2 function. 
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Figure 4.2. TRPM2 Knockout cultures are protected from Aβ toxicity.  
Hippocampal cultures at 3 weeks in vitro were either left untreated, or treated for 24 
hours with 1µM oligomerized Aβ1-42. Relative to untreated WT (n=6), and KO (n=7) 
cultures, 1µM oligomerized Aβ1-42 significantly reduced viability as measured by MTT 
assay in WT cultures, but not in KO cultures (n=8/group). *p<0.05, one-way ANOVA 
followed by post-hoc Tukey’s test. 
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Figure 4.3. Aβ indirectly potentiates TRPM2 currents 
(A) TRPM2 currents were generated in cultured hippocampal neurons at 3-4 weeks in 
vitro. Cells were treated for 24 hours with either 1µM oligomerized Aβ1-42 (n = 17) or 
vehicle control (n = 15). Currents were normalized to capacitance to control for 
variation in cell size. Results demonstrate a current density of -10.64 ± 1.03 pA/pF 
(n=15) in control, and -17.01 ± 2.13 pA/pF (n=17) in the Aβ1-42 treated group. 
(p=0.015); (B) HEK293-TRPM2 cells were similarly pretreated with either vehicle 
control (n=7) or 1µM Aβ1-42 oligomers for 24 hours. Currents were induced with 
0.1mM ADPR in the patch pipette. Treatment with Aβ1-42 did not alter TRPM2 
amplitude in these cells (p=0.67).  
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4.3.1 Fyn Potentiates TRPM2 Currents 
A growing body of literature implicates Fyn as a critical player in synaptic 
deficits and neurotoxicity associated with Alzheimer’s disease (Yang et al., 2011). 
Therefore, we examined whether Fyn could regulate TRPM2 function. Cultured 
hippocampal neurons at 3-4 weeks in vitro were used to examine whether currents 
elicited from endogenously expressed TRPM2 are enhanced by recombinant Fyn . 
Several studies have demonstrated that Fyn regulates NMDARs, enhancing 
phosphorylation and activity of the receptor (Salter & Kalia, 2004; Yang, Trepanier et 
al., 2011); therefore, in order to exclude any effect of Fyn on the NMDAR, a voltage-
ramp protocol was used to elicit a TRPM2 response. Currents were generated with 0.3 
mM ADPR, with or without 1 U/mL Fyn, in the patch pipette. Ramps were applied 
either immediately after breakthrough (n=5/group), or after 10 minutes to allow Fyn to 
diffuse into the cell (n=3/group). Results from both protocols were combined. As shown 
in Figure 4.4A-C, a significant increase in TRPM2 current is observed when Fyn is 
delivered via patch pipette in comparison to controls (Fyn, -1087 ± 134.2, N=10; 
control, -607.4 ± 121.1, N=9; p<0.05). 
HEK 293 cells stably expressing inducible flag-tagged TRPM2 (HEK293-
TRPM2) used to examine whether inclusion of Fyn (1U/mL) in the patch pipette 
directly enhances TRPM2 currents. As shown in figure 4.4D, when compared with 
control (-3743 ± 477.8, N=8) recombinant Fyn significantly increased TRPM2 currents 
(-5470 ± 425.4, N=8). 
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Figure 4.4. Fyn potentiates TRPM2 currents 
TRPM2 currents were generated using a voltage ramp protocol in cultured hippocampal 
pyramidal neurons with 0.3mM ADPR in the patch pipette. Dashed line indicates 
application of 0 Ca2+ ECF. (A) Representative control recording; (B) Representative 
Fyn (1U/mL) recording; (C) Compared with controls (-607.4 ± 121.1, N=9), Fyn (1 
U/mL, -1087 ± 134.2, N=10) significantly augmented TRPM2 currents; (D) TRPM2 
currents were generated in HEK293-TRPM2 cells with 0.1 mM ADPR in the patch 
pipette. When compared with controls (-3743 ± 477.8, N=8), Fyn (1 U/mL, -5470 ± 
425.4, N=8) significantly potentiates TRPM2 amplitude. 
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4.3.2 Fyn Phosphorylates TRPM2  
We next examined whether Fyn promotes TRPM2 tyrosine phosphorylation in 
HEK293-TRPM2 cells transfected with various Fyn constructs. Fyn kinase was cloned 
into a pcDNA3.1 vector and site directed mutagenesis was used to produce a 
consitutively active form of Fyn kinase (Fyn Y531F) as well as an inactive Fyn kinase 
(Fyn K299M). These forms of Fyn have been previously described and characterized 
(Maulon et al., 2001; Twamley et al., 1992). HEK293-TRPM2 cells were transfected 
with these constructs or empty vector control, and induced to express TRPM2. TRPM2 
was immunoprecipitated, run by SDS-PAGE, and probed for tyrosine phosphorylation 
(Figure 4.5). Results demonstrate that there is a significant difference between groups 
(p= 0.0124), with constitutively active Fyn enhancing TRPM2 tyrosine phosphorylation 
by approximately 6-fold over WT Fyn (p <0.05, one-way ANOVA followed by post-
hoc Tukey’s test). 
 
4.3.3 Fyn Co-Immunoprecipitates with TRPM2 
To examine whether Fyn interacts with TRPM2, TRPM2 pull-downs from 
HEK293-TRPM2 cells transfected with the various Fyn constructs were run by SDS-
PAGE and probed for Fyn. Indeed, Fyn interacts with TRPM2.  Interestingly, a 
significant difference between groups was observed (p = 0.009), with an enhanced 
interaction observed with the Fyn Y531F constitutively active mutant relative to WT 
(Figure 4.6A,B, p < 0.05). No significant difference between Y531F and WT Fyn input 
was observed (data not shown), suggesting that the interaction between Fyn and 
TRPM2 is enhanced when Fyn kinase is active. 
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Figure 4.5. TRPM2 tyrosine phosphorylation by Fyn. 
HEK293-TRPM2 cells were transfected with empty vector (EV), wildtype Fyn (WT), 
constitutively active Fyn (Y531F), or inactive Fyn (K299M). Flag-tagged TRPM2 
channels were immunoprecipitated from protein lysates and probed for tyrosine 
phosphorylation, and were subsequently striped and re-probed for TRPM2. Normalized 
values (pY TRPM2 / total TRPM2) were compared between groups (n=4 per 
treatment). (A) Representative blot. (B) A significant increase in tyrosine 
phosphorylation of TRPM2 is observed when co-transfected with constitutively active 
Fyn. Results are analyzed by one-way ANOVA followed by post-hoc Tukey’s test. 
Identical letters at top of bars indicate no significant difference between groups 
(p>0.05). 
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Figure 4.6. TRPM2 Interacts with Fyn 
In 4 separate experiments, HEK293-TRPM2 cells were transfected with empty vector 
(EV), wildtype Fyn (WT), constitutively active Fyn (Y531F), or inactive Fyn (K299M). 
Flag-tagged TRPM2 channels were immunoprecipitated from protein lysates, and 
immunoprecipitates were then run by SDS-PAGE, transferred to a nitrocellulose 
membrane, and probed for Fyn. To control for variations in TRPM2 expression and 
pull-down, the Fyn signal was normalized to flag-TRPM2 (A) Representative blot. (B) 
Fyn was co-immunoprecipitated with TRPM2 irrespective of the Fyn variant used. A 
significant increase in pull-down was observed with constitutively active Fyn (Y531F) 
relative to all other groups. Results are analyzed by one-way ANOVA followed by post-
hoc Tukey’s test. Identical letters at top of bars indicate no significant difference 
between groups (p>0.05). 
  
138 
 
139 
 
 
4.3.4 Fyn(39-57) Peptide Attenuates TRPM2 Currents 
Our current results suggest that Fyn is an important regulator of TRPM2. We 
therefore wanted to examine whether a peptide developed against the unique domain of 
Fyn could inhibit TRPM2 currents. This peptide corresponds to Fyn amino acids 39-57, 
and is proposed to disrupt interactions between Fyn and target or scaffolding proteins 
((Yang, Trepanier et al., 2011). As shown in Figure 4.7, TRPM2 currents of -692.0166 
+/- 88.57842 pA in amplitude are elicited in control conditions in cultured hippocampal 
neurons (n=12) after 25 minutes of recording; however, inclusion of the Fyn(39-57) 
peptide (25 ng/mL in the patch pipette) significantly diminished the TRPM2 response (-
224.2 +/- 24.2 pA, n=9).  
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 Figure 4.7. Fyn(39-57) peptide attenuates TRPM2 in hippocampal neurons 
Cultured hippocampal neurons at 3-4 weeks in vitro were used to assess the effect of a 
the Fyn(39-57) mimetic peptide. In the absence of ADPR, repeated applications of 
NMDA activates TRPM2 and enhances the holding current to -692.0166 +/- 88.57842 
pA after 25 minutes (Fyn CTL, n=12). Inclusion of the Fyn(39-57) peptide (25 ng/mL) 
in the patch pipette significantly attenuates the TRPM2 response, resulting in a current 
of -224.2 +/- 24.2 pA after 25 minutes (Fyn I, n=9). 
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4.4 Discussion 
 In this study, we demonstrate a role for TRPM2 in Aβ mediated cell death, and 
also examined the physical and functional link between Fyn kinase and TRPM2 
channels. We employed cultured hippocampal neurons to demonstrate that the genetic 
deletion of TRPM2 attenuates the decrease in cell viability induced by a 24 hour 
treatment with 1µM oligomeric Aβ. One study had previously concluded that a 
dominant negative form of TRPM2 and knock-down of TRPM2 can protect against Aβ-
mediated cell death (Fonfria et al., 2005). Importantly, this preliminary finding was 
investigated using 20 µM Aβ in striatal cultures; however, degeneration in Alzheimer’s 
disease occurs within the basal forebrain cholinergic neurons, entorhinal cortex, 
hippocampus, and cortex (Coyle et al., 1983; Gomez-Isla et al., 1996)(Coyle et al., 
1983; Gomez-Isla et al., 1996), and it is the oligomeric, not monomeric, form of Aβ that 
has been shown to induce an influx of intracellular calcium, significantly increase 
oxidative stress, and be particularly toxic to neurons (De Felice et al., 2007; Demuro et 
al., 2005; Lambert et al., 1998). The use of hippocampal cultures, along with use of 
oligomeric Aβ used in this study more accurately reflects the pathological conditions 
associated with Alzheimer’s disease, and implicates the channel in the disease process. 
Subsequent studies should be designed to assess whether genetic deletion of TRPM2 
can modify morbidity or mortality in transgenic models of Alzheimer’s disease. 
Following exposure to Aβ oligomers, TRPM2 currents are enhanced in cultured 
hippocapal neurons. This increase in current cannot be recapitulated in HEK cells 
expressing the TRPM2 channel. This suggests that Aβ enhances TRPM2 currents 
through an indirect mechanism. We hypothesize that the pathway will include Fyn 
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kinase. Therefore, we examined whether Fyn kinase could regulate the TRPM2 channel. 
In cultured hippocampal pyramidal neurons, we demonstrate that inclusion of Fyn 
kinase in the patch pipette increases TRPM2 current density when compared with 
controls. In addition, we used HEK293-TRPM2 cells transfected with empty vector or 
various forms of Fyn to demonstrate that TRPM2 is tyrosine phosphorylated by Fyn 
kinase, and this phosphorylation is significantly enhanced with constitutively active Fyn 
relative to WT Fyn. Furthermore, we demonstrate that Fyn interacts with TRPM2, and 
this interaction may be increased when Fyn is active. A peptide which mimics the 
unique domain of Fyn disrupts TRPM2 activation in cultured hippocampal pyramidal 
neurons.  
Further experiments are required to assess whether Fyn is involved in the 
potentiation of TRPM2 currents by Aβ. Furthermore, it is unclear whether the 
interaction between Fyn and TRPM2 is direct or through a separate scaffolding protein. 
Analysis of the structure of TRPM2 reveals several proline rich motifs (PxxP), which 
could be involved in binding to the SH3-domain of Fyn kinase. These motifs are located 
in both the N- and C- terminal portions of TRPM2 at amino acids 544-547, 551-554, 
575-578, 1078-1081, 1248-1251, and 1324-1327.  Deletion of one of both of the N-
terminal PxxP motif at 544-547 and 551-554 does not alter activation of TRPM2 by 
ADPR or H2O2 (Kuhn et al., 2009). Whether any PxxP motifs in TRPM2 participate in 
the interaction between Fyn and TRPM2 has not been investigated. Further research is 
also required to identify tyrosine phosphorylation sites on TRPM2 targeted by Fyn. The 
predictive software programs GPS 2.1 and PhosphoNet online application identify 10 
putative sites on TRPM2 which may be phosphorylated by Fyn. These sites are Y74, 
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Y142, Y523, Y682, Y1127, Y1132, Y1271, Y1301, Y1349 and Y1503. Studies are 
currently in progress to identify the site(s) on TRPM2 which are phosphorylated by 
Fyn.  
Our current results show the importance of continuing studies to determine the 
pathway through which TRPM2 currents are augmented by Aβ. Whether Fyn 
participates in this effect remains to be elucidated. A more complete understanding of 
this pathway may help to identify whether TRPM2 or the interaction between Fyn and 
TRPM2 could represent a potential target for development of novel therapeutics in AD. 
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5. Discussion 
TRPM2 is a Ca2+ permeable channel activated by oxidative stress which has also been 
tightly linked to cell death (Takahashi et al., 2011). The highest level of TRPM2 
expression is observed in the brain, where TRPM2 is expressed in several cell types 
including pyramidal neurons of the hippocampus (Fonfria et al., 2006; Olah et al., 
2009). The purpose of this PhD thesis was to determine the physiological role of 
TRPM2 in these neurons, and elucidate novel pathways which regulate channel 
expression or function. A combination of electrophysiology and molecular biology 
approaches in cultured cell lines, primary hippocampal cultures, and hippocampal slice 
preparations were employed. Results presented in this thesis demonstrate that: (1) 
TRPM2 participates in NMDAR-dependent LTD by regulating GSK-3β activity, as 
well as expression of AMPAR and PSD-95 (Xie et al., 2011); (2) TRPM2 activity is 
enhanced in cultured hippocampal neurons over time in vitro due to the loss of tonic 
inhibition by GSH (Belrose et al., 2012); (3) TRPM2 plays a role in Aβ toxicity, 
potentially through a pathway involving Fyn, a tyrosine kinase which regulates TRPM2 
in an activity dependent manner. This section will address the significance and 
implications of these findings. 
 
5.1 TRPM2 Participates in Synaptic Plasticity 
This thesis was the first to characterize the physiological role for TRPM2 in 
hippocampal pyramidal neurons. Employing TRPM2 knockout (KO) mice allowed us 
to validate the functional expression of TRPM2 in hippocampal pyramidal neurons. We 
determined that TRPM2 contributes to NMDAR-dependent LTD at hippocampal CA3-
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CA1 synapses. The absence of TRPM2 does not alter NMDAR currents or NMDAR 
subunit composition. Similarly, no change in VDCC currents is observed in cultured 
hippocampal pyramidal neurons from KO animals relative to WT control. Instead, the 
loss of NMDAR-dependent LTD in KO hippocampal slices results from increased 
inactivation of GSK-3β, and a reduction in the expression of PSD-95 and AMPARs. 
The loss of NMDAR-LTD could be recapitulated with the TRPM2 antagonist 
clotrimazole, demonstrating that the observed changes in synaptic plasticity were not 
due to developmental changes induced by genetic deletion of TRPM2. Furthermore, 
increasing the activity of GSK-3β by treatment with quinpirole, a D2 receptor agonist, 
rescued LTD induction.  
The signaling pathway through which TRPM2 regulates GSK-3β activity is 
likely to involve Ca2+. The increase in Ser9 phosphorylation in KO animals could 
suggest a decrease in activity of a Ca2+-dependent phosphatase. Calcineurin (also 
known as PP2B), a phosphatase regulated by Ca2+, dephosphorylates GSK-3β at Ser9, 
and could mediate the change in GSK-3β activation downstream of TRPM2 (Y. Kim et 
al., 2009). Whether calcineurin activity is decreased in KO hippocampal tissue has not 
yet been assessed. 
The decrease in AMPAR and PSD-95 expression in KO hippocampal slices also 
requires further exploration. This result, combined with a reduced AMPA/NMDA ratio, 
and a diminished mEPSC amplitude in KO slices, suggests that the contribution of 
AMPAR to excitatory synaptic transmission is reduced when TRPM2 is absent. The 
current study used total hippocampal lysates to assess AMPAR and PSD-95 expression. 
Whether the reduction in AMPAR is synapse specific, extrasynaptic, or was uniform 
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across the cell was not assessed. We demonstrated that clotrimazole could inhibit 
NMDAR-dependent LTD. Whether this treatment also produced a reduction in PSD-95 
and AMPAR, or whether the loss of expression is due to a prolonged loss of TRPM2 or 
development changes due to genetic deletion of TRPM2 was not investigated.  Lastly, 
the mechanism responsible for reduced AMPAR and PSD-95 expression was not 
explored. Whether a change in AMPAR and PSD-95 is due to a reduced transcription, 
translation, trafficking to the cell membrane, or enhanced degradation, should be 
explored to identify potential pathways through which TRPM2 may be regulating 
AMPAR and PSD-95 expression. 
The behavioural consequences resulting from the genetic deletion of TRPM2 is 
still under investigation. Preliminary results in our lab have shown that TRPM2 KO 
mice perform the same as their WT controls on tests of locomotion, anxiety, and spatial 
learning. Specifically, no differences are observed between WT and KO animals at 9 
months of age on the open field, elevated plus maze, Barnes maze, or object recognition 
tasks (M. Chen et al., unpublished). The absence of NMDAR-dependent LTD provides 
some insight into which behavioural tasks should be examined next in TRPM2 KO 
animals relative to controls. Specifically, the absence of LTD has been shown to impair 
behavioural flexibility, which can be evaluated by reversal learning in the Morris water 
maze and by the delayed non-match to place T-maze task (J. I. Kim et al., 2011). 
 Identification of the physiological role of TRPM2 in hippocampal pyramidal 
neurons not only contributes to the characterization of the TRPM2 channel, but it also 
furthers our understanding of the cellular mechanisms underlying learning and memory. 
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Furthermore, it allows us to identify potential consequences of directly inhibiting 
TRPM2 in a clinical setting. 
 
5.2 TRPM2 Activity and Aging 
TRPM2 currents are enhanced in cultured hippocampal neurons over time in 
vitro. The functional increase in TRPM2 currents is attributed to depletion of GSH with 
age, and the loss of tonic inhibition of the channel by GSH. Contrary to the previously 
proposed mechanisms of TRPM2 inhibition by GSH, inhibition is not due to the 
reducing effects of GSH. Inhibition by GSH is also independent of protein interactions 
with the cysteine residue in GSH since the effects of GSH can be recapitulated with 
ophthalmic acid, an analogue with an aminobutyrate group replacing the cysteine 
residue. The interaction between GSH and TRPM2 may play an important role in aging 
and neurological diseases associated with depletion of GSH.  
A shift in the concentration-response curve shows that GSH produces a 3.5fold 
inhibition of the TRPM2 response to the intracellular agonist, ADPR. Interestingly, 
preliminary evidence suggests that ADPR may enhance the interaction between GSH 
and TRPM2 (J. Belrose, unpublished). Rather than GSH competing for the ADPR 
binding site on TRPM2, this result raises the possibility that GSH may function by 
binding to ADPR and disrupting proper channel activation. In support of this idea, a 
previous publication demonstrated that GSH covalently binds to ribose through an 
interaction between the glutamyl group of GSH and the aldehyde group of ribose 
(Januel et al., 2003). Whether this reaction also occurs between GSH and ADPR has not 
yet been assessed. 
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 To determine whether TRPM2 currents are also elevated with age in vivo, 
TRPM2 currents can be recorded from aged WT hippocampal slices. As mentioned 
previously, no TRPM2 KO phenotype has been identified out to 9 months of age on the 
open field, elevated plus maze, object recognition, or Barnes Maze (M. Chen, 
unpublished). The results presented in this thesis suggest that a behavioural phenotype 
may be more apparent in aged mice.  
 In addition to normal aging, GSH is also reduced in Parkinson’s disease (Martin 
& Teismann, 2009). TRPM2 is expressed and functional in dopaminergic neurons of the 
substantia nigra affected by Parkinson’s disease (Chung, Freestone, & Lipski, 2011). 
Most Parkinson’s disease cases are sporadic, with familial Parkinson’s accounting for 
less than 15% of cases. Transgenic mouse models targeting the various genes 
implicated in familial Parkinson’s disease have not yet produced a model that displays 
nigrostriatal neuronal degeneration (Blandini & Armentero, 2012). The 1-methyl 4-
phenyltetrahydropyridine (MPTP) systemic neurotoxin model of Parkinson’s disease, 
however, is selectively toxic to the dopaminergic neurons in the nigrostriatal pathway 
within one week following injection (Blandini & Armentero, 2012). To examine 
whether TRPM2 is implicated in Parkinson’s disease, TRPM2 WT and KO animals 
could be assessed for performance on a grid-walking test and treadmill activity 
immediately prior to and two weeks following injection of vehicle control or MPTP.   
 In addition to GSH depletion in Parkinson’s disease, GSH is also reduced in 
progressive supranuclear palsy, bipolar disorder, major depressive disorder, and 
schizophrenia (Martin & Teismann, 2009; Perry, Godin, & Hansen, 1982; Sian et al., 
1994)(Anderson & Sims, 2002; Bragin et al., 2010; Rehncrona & Siesjo, 1979; Salemi 
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et al., 2009)(Do et al., 2000; Gawryluk et al., 2011). Several studies have linked SNPs 
in TRPM2 to bipolar disorder (Kostyrko et al., 2006; McQuillin et al., 2006; Xu et al., 
2006; Xu et al., 2009). Whether the other neurodegenerative and neuropsychiatric 
disorders associated with GSH depletion demonstrate SNPs in TRPM2 has not yet been 
investigated. 
 
5.3 Potential Implications to Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting 
memory, orientation, and reasoning. In Canada, the disease is estimated to affect 1.5% 
of our total population (Alzheimer Society of Canada, 2010).  
Soluble oligomers of Aβ initiates a toxic cascade, resulting in the pathological 
modification of tau, and subsequent targeting of Fyn kinase to NMDARs (Ittner et al., 
2010). The interaction between Fyn and tau is disrupted in tau -/-and tau74 mice 
(transgenic mice which express only the N-terminal projection domain of tau), 
decreasing the targeting of Fyn to the synapse. A reduction in mortality and cognitive 
deficits in an AD mouse model (APP23) are observed when these mice are crossed with 
tau -/- or tau74 mice. The Tat-NR2B9c peptide, a peptide which disrupts the interaction 
between NMDAR subunit 2B (GluN2B) and PSD-95, similarly rescued the memory 
deficits and lethality in APP23 mice (Ittner et al., 2010). 
In agreement with the finding that Fyn is instrumental in AD, behavioural 
deficits and neurotoxicity in an AD mouse model can be enhanced with overexpression 
of Fyn (Chin et al., 2004; Chin et al., 2005). Similarly, hippocampal slices from Fyn 
knockout mice are protected from cell death induced by soluble oligomeric Aβ 
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(Lambert et al., 1998). In contrast, in the triple transgenic (3xTg) model of Alzheimer’s 
disease, 3xTg(+/-) mice exhibit augmented spatial learning deficits and Aβ 
accumulation when Fyn is knocked down (Fyn+/-) relative to controls 
(Fyn(+/+)3xTg(+/-)) (Minami et al., 2012). This last result is not surprising when one 
considers the role for Fyn in LTP induction (Grant et al., 1992; Kojima et al., 1997). 
Furthermore, Fyn plays a critical role in oligodendrocyte production and subsequent 
neuronal myelination (Kramer-Albers & White, 2011; Osterhout et al., 1999). A 
conditional knockout of Fyn kinase in an AD mouse model would help to clarify 
whether the enhanced deficits in the 3xTg(+/-) mice are a result of developmental 
changes, or whether the effect can also be recapitulated when Fyn is knocked out after 
disease onset. Until this phenomenon has been explored further, the study by Minami 
and colleagues (2012) raises the possibility that global inhibition of Fyn may not 
provide therapeutic benefit to individuals diagnosed with AD. Further research into 
pathways altered by Fyn may uncover a more targeted approach for pharmacological 
intervention in AD. 
As discussed previously, the toxic triad of tau, Fyn, and NMDARs are unlikely 
to explain all of the neurotoxicity and synaptic deficits observed in AD. Here, we 
propose that TRPM2 may participate in this protein complex. First, we demonstrate that 
TRPM2 plays a role in decreasing synaptic strength, a hallmark of AD (Xie et al., 
2011). We further demonstrate that currents are enhanced by glutathione depletion over 
time in vitro, raising the possibility that glutathione depletion with age in vivo may 
produce an age-dependent increase in TRPM2 currents (Belrose et al., 2012). In chapter 
4, we demonstrated that genetic deletion of TRPM2 protects against the reduction in 
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cell viability associated with oligomeric Aβ treatment. Furthermore, we demonstrated 
that TRPM2 currents are indirectly enhanced by Aβ, and that the channel is regulated 
by Fyn, an important player in AD (Belrose, Johnson, Li, Caetano, MacDonald & 
Jackson, unpublished).  
A future direction of this project will examine the hypothesis that knockout of 
TRPM2 will protect against memory deficits and mortality in a mouse model of 
Alzheimer’s disease. To examine whether knockout of TRPM2 also protects against 
mortality and cognitive deficits in an Alzheimer’s disease mouse model, we have 
crossed TRPM2+/- mice with APPswePS1dE9 transgenic mice. This model of 
Alzheimer’s disease co-expresses the swedish mutation of APP with a presinilin (PS1) 
lacking exon 9 (Jankowsky et al., 2004; Malm, Koistinaho, & Kanninen, 2011; Xiong et 
al., 2011) Four genotypes (TRPM2+AD-, TRPM2-AD-, TRPM2+AD+, AND TRPM2-
AD+) will be tested on the open field, elevated plus maze, object recognition, Barnes 
maze, and Morris Water Maze to assess for changes in locomotion, anxiety, and 
memory. In APPswePS1dE9 mice, memory deficits on the Morris water maze appear at 
12 months of age (Xiong et al., 2011). We propose that the deficits observed in the 
TRPM2+AD+ will be attenuated in the TRPM2-AD+. 
We also hypothesize that the enhancement of TRPM2 currents by Aβ oligomers 
involves Fyn kinase. To examine this hypothesis, shRNA targeting Fyn will be used to 
knock-down expression of Fyn. A lentiviral system will be used to infect cultured 
hippocampal neurons with Fyn shRNA or scrambled shRNA control. In addition to 
allowing expression of shRNA driven by a U6 promoter, the transfer vector (pLB) used 
also allows expression of GFP with expression driven by a CMV promoter. Infection 
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rates in excess of 80% have routinely been achieved in our cultured hippocampal 
neurons.  If Fyn is involved in potentiation of TRPM2 current by Aβ, we anticipate that 
knockdown of Fyn kinase would attenuate Aβ-mediated enhancement of TRPM2 
currents in cultured neurons relative to scrambled shRNA infected controls. 
 
5.4 Regulation of TRPM2 by Fyn 
Fyn interacts with and phosphorylates TRPM2, and enhances TRPM2 currents. 
This is the first study to identify a kinase which acts upon TRPM2, and represents a 
novel regulatory mechanism which may play an important role in oxidative stress and 
Alzheimer’s disease. It is unclear whether the interaction between Fyn and TRPM2 is 
direct or through a separate scaffolding protein. Analysis of the structure of TRPM2 
reveals several proline rich motifs (PxxP), which could be involved in binding to the 
SH3-domain of Fyn kinase. Whether any PxxP motifs in TRPM2 participate in the 
interaction between Fyn and TRPM2 has not been investigated. Alternatively, Fyn may 
interact with TRPM2 through an intermediate protein such as a scaffolding protein. The 
precise nature of the interaction between TRPM2 and Fyn requires further exploration, 
and may lead to the development of a more specific inhibitory peptide.  
The current study used intracellular applications of recombinant Fyn kinase to 
assess the effect on TRPM2 currents. We demonstrated that acute Fyn kinase enhanced 
TRPM2 current amplitude; however, it is unclear whether a more chronic exposure to 
activated Fyn would produce the same effect. Results from western blotting 
experiments raise the possibility that Fyn exerts a dichotomous effect on TRPM2: 
acutely enhancing currents, and reducing TRPM2 expression in more chronic 
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conditions. Total cell lysate from HEK293-TRPM2 cells transfected with the various 
Fyn constructs were separated by SDS-PAGE to assess TRPM2 and Fyn expression. To 
our surprise, we consistently observed a decrease in TRPM2 expression normalized to 
β-actin when constitutively active Fyn was transfected (Figure 5.1). Importantly, no 
change in β-actin levels was observed between groups (p>0.05). This decline in TRPM2 
expression may represent a difference in protein production, trafficking, endocytosis 
and degradation, or cell proliferation and viability. If cells expressing TRPM2 have 
diminished proliferation, or undergo apoptosis or necrosis in response to overexpression 
of constitutively active Fyn, we would expect a decrease in total protein levels in lysates 
collected from these cells. Analysis of protein concentration reveals that there is no 
difference in protein levels between the groups (one way ANOVA, p = 0.68, data not 
shown). Further research is needed to first assess whether surface expression of TRPM2 
is altered, and subsequently to assess whether a change in protein production, 
trafficking, endocytosis, or degradation underlies the reduction of TRPM2 in response 
to constitutively active Fyn. This result also raises the intriguing possibility that, 
although acute Fyn enhances TRPM2 currents, chronically active Fyn may decrease 
TRPM2 activity through a reduction in TRPM2 expression.  
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Figure 5.1. Constitutively active Fyn decreases TRPM2 expression.  
Total protein from HEK-TRPM2 cells transfected with EV, WT, constitutively active 
(Y531F), or inactive (K299M) Fyn were separated by SDS-PAGE and analyzed for 
flag-TRPM2 and Fyn input, normalized to β-actin expression. (A) Representative blots; 
(B) TRPM2 input normalized to β-actin demonstrates a significant reduction in TRPM2 
expression relative to empty vector (n=4/treatment) (C) Fyn input normalized to β-actin 
demonstrates expression of Fyn with transfection of each construct. A significant 
reduction in Fyn expression is observed with K299M relative to Y531F; however, 
neither construct exhibit a significant change in expression relative to WT Fyn (n=4). 
Results are analyzed by one-way ANOVA followed by post-hoc Tukey’s test. Identical 
letters at top of bars indicate no significant difference between groups (p>0.05).
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 Interestingly, TRPM7, another member of the TRPM subfamily of cation 
channels, may be regulated by Src kinase, a related kinase with significant homology to 
Fyn (Jiang, Newell, & Schlichter, 2003). Similar to the inhibition of TRPM2 by 
Fyn(39-57), TRPM7 currents are inhibited with Src(40-58) in microglia (Jiang et al., 
2003). Considering the similarity between TRPM2 and TRPM7, as well as the 
homology between Fyn and Src kinase, we wondered whether Src kinase may also 
regulate TRPM2 channels. In HEK293-TRPM2 cells, we demonstrate that recombinant 
Src (1U/mL) in the patch pipette significantly potentiates TRPM2 currents (-6193 ± 
505.1, N=10) relative to controls (-4831 ± 213.9, N=7) as shown in Figure 5.2.  
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Figure 5.2. Src potentiates TRPM2 currents 
TRPM2 currents were generated in HEK293-TRPM2 cells with 0.1 mM ADPR in the 
patch pipette. When compared with controls (-4831 ± 213.9, N=7), Src (1 U/mL, -6193 
± 505.1 N=10) significantly potentiates TRPM2 amplitude 
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5.5 Conclusion 
Our lab previously demonstrated that TRPM2 is expressed and functional in 
hippocampal pyramidal neurons; however, the physiological role and various pathways 
regulating TRPM2 had not yet been established (Olah et al., 2009). Substantial evidence 
demonstrates that TRPM2 plays an important role in cell death (Takahashi et al., 2011). 
Here, we identified that TRPM2 is required for NMDAR-dependent LTD through the 
regulation of GSK-3β activity (Xie et al., 2011). We examined TRPM2 currents over 
time in vitro and provide evidence that TRPM2 currents are enhanced with GSH 
depletion (Belrose et al., 2012). This raises the possibility that TRPM2 currents may be 
enhanced with normal aging and in the various neurodegenerative and psychiatric 
disorders associated with GSH depletion. Furthermore, we demonstrate that cultured 
hippocampal neurons derived from TRPM2 KO mice show an attenuated loss of cell 
viability following treatment with Aβ oligomers when compared with WT cultures. We 
also demonstrate that Fyn kinase is capable of interacting with, and phosphorylating 
TRPM2. Delivery of recombinant Fyn through the patch pipette potentiates TRPM2 
currents. Combined, this data raises the possibility that TRPM2 may play a role in 
Alzheimer’s disease pathology (Figure 5.3) 
Elucidating the properties and physiological role(s) of TRPM2 is still in the 
early stages; however, these findings open the door to several subsequent studies on the 
significance of TRPM2 to normal function and potential contribution to various 
neurological diseases. 
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Figure 5.3 Summary 
In addition to a role for TRPM2 in cell death, the channel also participates in decreasing 
synaptic strength via regulation of GSK-3β activity. TRPM2 is tonically inhibited by 
GSH which can be depleted with age. Furthermore, the channel is activated by Fyn, a 
Src-family kinase implicated in Alzheimer’s disease. Treatment with Aβ, the initiating 
factor of Alzheimer’s pathogenesis, enhances TRPM2 currents through an unknown 
mechanism. This may involve Fyn kinase since treatment with Aβ results in the 
downstream hyperphosphorylation of tau via several kinases including GSK-3β, and the 
mislocalization of Fyn in response to pathologically modified tau.  
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